

# **Advance ZincTek Limited**

**ACN 079 845 855**

## **Annual Report**

**For the Year Ended 30 June 2025**

**ACN 079 845 855**

**ASX Code: ANO**

## **Contents**

### **For the Year Ended 30 June 2025**

|                                                                         | Page |
|-------------------------------------------------------------------------|------|
| Chairman's Letter                                                       | 1    |
| Managing Director's Review                                              | 3    |
| Directors' Report                                                       | 5    |
| Auditor's Independence Declaration                                      | 15   |
| Consolidated Statement of Profit or Loss and Other Comprehensive Income | 16   |
| Consolidated Statement of Financial Position                            | 17   |
| Consolidated Statement of Changes in Equity                             | 18   |
| Consolidated Statement of Cash Flows                                    | 19   |
| Notes to the Financial Statements                                       | 20   |
| Independent Auditor's Report                                            | 54   |
| Corporate Governance Statement                                          | 59   |
| Shareholders Information                                                | 59   |
| Disclosure Regarding Forward Looking Statement                          | 61   |


## Chairman's Letter

The profit before tax of \$2.024 million is the direct result of decisions taken by the Board in FY 24 which include:

- The decision to remove distributor exclusivity in the USA and Canada and transition to 4 customers resulting in sales of \$6.15 million compared to FY24 of \$2.54 million, an increase of 140.84%.
- The decision to close our Perth facility which resulted in cost savings of approximately \$750,000 in FY25 and further savings predicted in FY26.

### USA Tariffs

Despite zinc oxide being excluded from previous announced USA tariffs on Australia, the threat around potential 250% tariffs on pharmaceuticals may negatively impact USA sales, even though there are no manufacturers of pharmaceutical grade zinc oxide in USA at present. Zinc oxide at this point, is a separate category from other pharmaceuticals, with no USA based manufacturers, so 250% tariffs may not apply. Obviously, this situation is dependent on how our Prime Minister handles the trade talks with the Trump Administration.



## Chairman's Letter Cont.

We also welcome the rising focus on consumer safety. Robert F. Kennedy Jr.'s "Make America Healthy Again" movement, advocating stricter regulation of chemicals in consumer products, aligns strongly with ANO's commitment to quality and safety. His recent challenge to sunscreen standards underscores the importance of robust health protections — an approach we believe should be matched with equal urgency by Australia's TGA and Federal Health Minister.

### Artificial Intelligence Impact on ANO

Artificial Intelligence will be a cornerstone of ANO's growth strategy in the years ahead. We are embedding AI capabilities across the business to enhance efficiency, accelerate innovation, and strengthen decision-making.

- **Sales & Business Development** – AI-powered analytics will enable us to identify market trends sooner, uncover new opportunities, and optimise customer engagement.
- **Product Development** – Machine learning tools are streamlining our R&D process, reducing time-to-market, and helping us create tailored, high-quality formulations that meet emerging health and sustainability demands.
- **Training & Capability Building** – Personalised AI-driven learning paths are equipping our people with the skills and insights needed to adapt quickly in a changing market.

Early adoption of AI has already delivered measurable gains in processing speed and reduced product development cycles. These initiatives are positioning ANO not just to respond to change, but to anticipate it — giving us a lasting competitive advantage.

### Project Management / CRM Software Implementation

The introduction of a business-specific software solution is scheduled for FY26. The modules — including CRM, Bill of Materials, manufacturing workflow scheduling, and project management — are designed to enhance operational efficiency and reduce indirect costs.

I would like to personally thank all staff for the significant work required to relocate the Perth operations to Brisbane and for embracing the implementation of AI across the business. Your adaptability and commitment have been vital to this transformation.



Lev Mizikovsky

Non-Executive Chairman

Dated: 29 August 2025

## Managing Director's Review

### Financial Performance

The operating profit before tax is \$2.024 million compared to FY24 loss of (\$0.990 million) up 304.84%.

Sales revenue for FY25 year to date is \$11.639 million, exceeding the full year FY24 revenue of \$9.320 million. This increase reflects stronger sales performance in the USA and operational efficiencies following the closure of the Perth facilities.

The current result was negatively impacted by the following non-recurring one-off items:

- Sapphire Matte product (refer ASX announcement dated 24 April 2025) (\$150,000 FY25 compared to \$1,020,000 FY24). Reduction of \$870,000 (down 85.29%).
- A non-cash expense of \$150,000 related to a staff share issue and Perth staff redundancy arrangements.
- Costs associated with the transfer and the installation of Perth production equipment to the Brisbane facility and the amount has been expensed.

### Production - Inventory Levels

- ANO has reduced finished goods inventory across all warehouses by \$221,000, while maintaining shorter lead times for distributors than competitors. However, ongoing tariff uncertainty will require higher stock levels in the USA, which is expected to negatively impact cash holdings in FY26. The Board is assessing capital management initiatives and will provide an update at the forthcoming Annual General Meeting.

### New Products

- **White Sapphire Matte / Glow**  
Over the past five months, we have distributed more than 200 samples through our network to prospective customers. Feedback has been encouraging. A number of test orders have been already received.
- **High Purity White Sapphire**  
Initial trials completed in July 2025 confirmed the need for further refinement to reduce impurities. We have identified over 16 potential applications, including three requiring TGA licensed manufacturing facilities, which ANO possess. The market opportunity extends to more than 600 potential new customers globally, highlighting the strong growth potential of innovation.
- **Magnesium Oxide**  
Successful trials have been completed, and marketing efforts are scheduled to begin in FY26. This product is expected to expand our portfolio and complement existing customer demand.
- **New Oxides**  
We have commenced sourcing raw materials to trial three new oxides that align with our ZinClear range. These oxides are targeted exclusively at the cosmetic sector and complement our existing range of zinc products.

### LinkedIn Campaigns

Over the past two months, we have been creating awareness of the dangers of certain ingredients used in chemical sunscreens through targeted LinkedIn campaigns.

- **Chemical UV Filters and Diabetes** (7 weeks)  
There are substantial links between homosalate, oxinoxate, and oxybenzone with endocrine disruptions, and consequently, plausible impacts on thyroid and oestrogen function, both critical to glucose regulations.  
8,254,588 impressions USA / Australia and 47,443 clicks through to the report.

## Managing Director's Review Cont.

- **Oxybenzone and Avobenzone and Asthma** (5 weeks)  
Oxybenzone and avobenzone breakdown byproducts, especially in chlorinated swimming pools, pose respiratory challenges for people with asthma or heightened chemical sensitivity.  
327,073 impressions USA / Australia and 13,213 clicks through to the report.
- **Homosalate and Breast Cancer** (1 week)  
Homosalate may reduce the effectiveness of breast cancer treatments and contribute to a potential relapse as it can increase the mobility and invasive activity of breast cancer cells and build resistance to current treatments.  
241,666 impressions USA / Australia and 9,727 clicks through to the report.

You can follow our campaigns by joining the company's LinkedIn page [Advance ZincTek \(ASX:ANO\) | LinkedIn](#)

I would like to thank our distributors, suppliers of key raw ingredients, and all staff — from administration through to senior management — for their continued support. Together, we remain focused on delivering the best outcomes for our customers and shareholders.



Geoff Acton  
Managing Director

Dated: 29 August 2025

## Directors' Report

### For the Year Ended 30 June 2025

Your directors present their report, together with the financial statements of the Group, being Advance ZincTek Limited (the "Company") and its controlled entities (the "Group"), for the financial year ended 30 June 2025.

#### 1. General information

##### Directors

The names of the directors in office at any time during, or since the end of, the year are:

| Names          | Position                                             |
|----------------|------------------------------------------------------|
| Lev Mizikovsky | Non-executive Chairman                               |
| Rade Dudurovic | Non-executive Director / Chairman of Audit Committee |
| Geoff Acton    | Managing Director                                    |

Directors have been in office since the start of the financial year to the date of this report unless otherwise stated.

##### Company Secretaries

The following persons held the position of Company Secretary during the financial year:

- Geoff Acton (B.Com, CA, GAICD)
- Narelle Lynch ("Cert Gov Prac")

##### Principal activities

During the year the principal continuing activities of the Group consisted predominantly of the manufacture of aluminium oxide powder (Alusion), zinc oxide dispersions and zinc oxide powder (collectively ZinClear) for the Personal Care Sector.

There were no significant changes in the nature of the Group's principal activities during the financial year.

#### 2. Operating results and review of operations for the year

##### Operating results

Please refer to the Chairman's Letter on page 1 of this report.

#### 3. Financial review

##### Review of financial position

The net assets of the Group have increased by \$1.389 million from \$34.380 million at 30 June 2024 to \$35.769 million at 30 June 2025.

#### 4. Other items

##### Significant changes in state of affairs

There have been no significant changes in the state of affairs of entities in the Group during the year.

##### Events after the reporting date

Except for the above, no other matters or circumstances have arisen since the end of the financial year which significantly affected or could significantly affect the operations of the Group, the results of those operations, or the state of affairs of the Group in future financial years.

##### Dividends paid or recommended

No dividends have been paid or declared during the financial year (2024: Nil).

## Directors' Report

### For the Year Ended 30 June 2025

#### 4. Other items

##### Future developments and results

The Group has established a solid platform from which to grow sales, improve margins and deliver profitability.

##### Material business risks

- Loss of manufacturing premises may impact our business in the short term. This is mitigated by us holding stocks in our overseas warehouse.
- Loss of our TGA licence may significantly impact our USA and Australian sales. We would still be able to sell in other jurisdictions. We have systems in place to meet the TGA requirements.
- Loss of major customer may impact our business. We have mitigated the risk by moving to multiple distributors. (e.g. USA from 1 to 4 distributors).
- The potential imposition of tariffs of up to 250% on pharmaceuticals by the Trump Administration may impact sales in the USA. ANO is increasing its stock levels in the USA to mitigate the potential impact of tariffs.

##### Environmental issues

No breaches of environmental regulations occurred during the year. We use PV panels to reduce electricity during manufacturing and use organic and vegan ingredients.

##### Indemnification and insurance of officers

The Directors, Secretaries and Officers of the Group and its controlled entities are insured for liabilities that include costs and expenses that may be incurred in defending civil or criminal proceedings that may be brought against the officers in their capacity as officers of entities in the Group.

The liabilities insured exclude any criminal, fraudulent, dishonest or malicious act or omission or improper use of information or position to gain a personal advantage.

The contract of insurance prohibits disclosure of the nature of the liability and the amount of the premium.

##### Shares under option

There are no un-issued shares of Advance ZincTek Limited under option at the date of this report.

##### Indemnity and insurance of auditor

The company has not, during or since the end of the financial year, indemnified or agreed to indemnify the auditor of the company or any related entity against a liability incurred by the auditor.

During the financial year, the company has not paid a premium in respect of a contract to insure the auditor of the company or any related entity.

##### Proceedings on behalf of the company

No person has applied to the Court under section 237 of the Corporations Act 2001 for leave to bring proceedings on behalf of the company, or to intervene in any proceedings to which the company is a party for the purpose of taking responsibility on behalf of the company for all or part of those proceedings.

## Directors' Report

### For the Year Ended 30 June 2025

#### 4. Other items

##### Information on directors

|                                      |                                                                                                                                                                                                                                                                                                                                                                               |
|--------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Lev Mizikovsky</b>                | <b>Non-executive Chairman</b>                                                                                                                                                                                                                                                                                                                                                 |
| Qualifications                       | FAICD                                                                                                                                                                                                                                                                                                                                                                         |
| Experience                           | Since 1977, Mr. Lev Mizikovsky has been a Fellow of the Australian Institute of Company Directors (AICD). He is a substantial shareholder in a number of other Queensland companies including Tamawood Limited (ASX: TWD), SenterpriSys Limited (NSX: SPS) and VeganicSKN Limited.                                                                                            |
| Special Responsibilities             | Member of all the Committees                                                                                                                                                                                                                                                                                                                                                  |
| Directorships held in other entities | Lev is the founding Director of Tamawood Limited which started in July 1989 and is Executive Chairman. He is Executive Chairman of SenterpriSys Limited and VeganicSKN Limited.                                                                                                                                                                                               |
| <b>Rade Dudurovic</b>                | <b>Non-executive Director / Chairman of Audit Committee</b>                                                                                                                                                                                                                                                                                                                   |
| Qualifications                       | B.Com (Hons), LLB (Hons)                                                                                                                                                                                                                                                                                                                                                      |
| Experience                           | Rade has an extensive background in private equity with strong exposure to industrial and branded consumer manufacturing and distribution businesses particularly in the Asian region. He has qualifications in commerce and law and is a CPA as well as Senior Fellow of FINSIA                                                                                              |
| Special Responsibilities             | Chairman of the Audit Committee. Chairman of the Nomination & Remuneration Committee.                                                                                                                                                                                                                                                                                         |
| Directorships held in other entities | Rade is Non-executive Director of Tamawood Limited (ASX: TWD), SenterpriSys Limited (NSX: SPS) and VeganicSKN Limited.                                                                                                                                                                                                                                                        |
| <b>Geoff Acton</b>                   | <b>Managing Director</b>                                                                                                                                                                                                                                                                                                                                                      |
| Qualifications                       | B.Com, CA, GAICD                                                                                                                                                                                                                                                                                                                                                              |
| Experience                           | Geoff brings to Advance ZincTek Ltd a vast number of strategic and operational capabilities in his over 20-year history with the Tamawood Group including as Chief Financial Officer and Company Secretary. Further, he has an in-depth knowledge of the renewable energy sector as head of the successful Renewable Energy Certificate trading business established in 2004. |
| Special Responsibilities             | Member of all the Committees                                                                                                                                                                                                                                                                                                                                                  |
| Directorships held in other entities | Geoff is Non-executive Director of VeganicSKN Limited.                                                                                                                                                                                                                                                                                                                        |

##### Company secretaries

**Geoff Acton** - appointed Company Secretary on 13 July 2015. Geoff is a chartered accountant and has more than 20-year history with Tamawood Limited in various capabilities including Director, Chief Financial Officer, Company Secretary and head of Tamawood's Renewable Energy Certificates trading business, which Geoff established in 2004.

**Narelle Lynch** "Cert (Gov Prac)"

Narelle was appointed joint company secretary on 9 August 2017.

## Directors' Report

### For the Year Ended 30 June 2025

#### Meetings of directors

The number of meetings of directors (including committees of directors) held during the financial year and the number of meetings attended by each director were as follows:

|                | Directors' Meetings       |                 | Audit Committee           |                 | Risk Committee            |                 | Nomination & Remuneration Meetings |                 |
|----------------|---------------------------|-----------------|---------------------------|-----------------|---------------------------|-----------------|------------------------------------|-----------------|
|                | Number eligible to attend | Number attended | Number eligible to attend | Number attended | Number eligible to attend | Number attended | Number eligible to attend          | Number attended |
| Lev Mizikovsky | 11                        | 11              | 2                         | 2               | 1                         | 1               | 2                                  | 2               |
| Rade Dudurovic | 11                        | 11              | 2                         | 2               | 1                         | 1               | 2                                  | 2               |
| Geoff Acton    | 11                        | 11              | 2                         | 2               | 1                         | 1               | 2                                  | 2               |

#### Non-audit services

The Board of Directors, in accordance with advice from the audit committee, is satisfied that the provision of non-audit services during the year is compatible with the general standard of independence for auditors imposed by the Corporations Act 2001 for the following reasons:

- all non-audit services are reviewed and approved by the audit committee prior to commencement to ensure they do not adversely affect the integrity and objectivity of the auditor; and
- the nature of the services provided do not compromise the general principles relating to auditor independence in accordance with APES 110: Code of Ethics for Professional Accountants (including Independence Standards) set by the Accounting Professional and Ethical Standards Board.

The total fees to the Group's external auditors, William Buck (QLD) for non-audit services during the year ended 30 June 2025 was Nil (2024: Nil).

#### Auditor's independence declaration

The lead auditor's independence declaration in accordance with section 307C of the *Corporations Act 2001* for the year ended 30 June 2025 has been received and can be found on page 15 of the financial report.

#### Remuneration report (audited)

This report details the nature and amount of remuneration for the key management personnel of the Group, including the Directors in accordance with the requirements of the Corporations Act 2001 and its Regulations, and has been audited in accordance with section 308(3C).

## Directors' Report

### For the Year Ended 30 June 2025

#### Remuneration policy

The performance of Advance ZincTek Limited and its subsidiaries ("Group") depends upon the quality of its key management personnel. To prosper, the Group must attract, motivate and retain highly skilled Directors and other key management personnel.

To this end, the Group embodies the following principles in its remuneration framework:

- Provide competitive rewards to attract high calibre key management personnel.
- Link executive rewards to shareholder value.

In accordance with best practice corporate governance, the structure of Non-executive Director and Executive remuneration is separate and distinct.

#### Non-executive Director Remuneration

##### Objective

The Board seeks to set aggregate remuneration at a level that provides the Group with the ability to attract and retain Directors of the highest calibre, and at a remuneration level within market rates.

##### Structure

The Company's Constitution and the ASX Business Rules specify that the aggregate remuneration of Non-executive Directors shall be determined from time to time by a general meeting. The aggregate remuneration that may be paid to Non-executive directors is \$350,000 exclusive of Superannuation Guarantee Levy. This remuneration may be divided among the non-executive directors in such a fashion as the Board may determine. Notice of any proposed increase in the total amount of remuneration payable to the non-executive directors must be given to members in the notice covering the general meeting at which the increase is to be proposed. The Board will seek approval from time to time as deemed appropriate.

The current directors' fees were last reviewed with effect from 1 July 2022. The Non-Executive Chairman receives no fees. Other Directors receive fees commensurate with their time commitment and responsibilities.

#### Executive Director Remuneration

##### Objective

The Board seeks to set aggregate remuneration at a level that provides the Group with the ability to attract and retain Directors of the highest calibre, and at a remuneration level within market rates.

##### Structure

The Board believes that, at this stage of the Group's development, and in light of the size of the Group and its executive team, senior manager and executive director remuneration should be comprised of the following three components:

- Fixed salary and benefits, including superannuation;
- Short-term performance incentives (bonus payments); and
- Long-term performance incentives (such as options, shares or performance rights)

In determining the level and make-up of executive remuneration, the Board considers external benchmarking information to help ensure that the Group provides a competitive and acceptable remuneration level and that the market value for executives and senior managers in similar companies considering the work that they are required to perform.

##### Short term performance incentives

Senior managers and executives may be eligible for bonus payments from time to time at the discretion of the Board, if the Board considers that any executive's contribution warrants such recognition. No bonuses have been awarded in this financial year.

##### Long-term performance incentives

There are no long term performance incentives in place with key management personnel and the executive director.

## Directors' Report

### For the Year Ended 30 June 2025

#### Remuneration policy

#### Company performance, Shareholder Wealth and Key Management Personnel Remuneration

The Board is cognisant of the link between Directors', and other key management personnel remuneration to the achievement of strategic goals and performance of the Group. In setting remuneration policy, the Group seeks to align key management personnel rewards with overall shareholder value creation.

The Board reviews senior management remuneration on a regular basis to ensure base remuneration and any performance payments are directly linked to the achievement of profit contribution targets.

Details of shareholder returns are provided below. Given the stage of commercialisation of the Group's products and technologies, shareholder returns have been adversely impacted by ongoing investment in research and product development.

|                                                        | 2025          | 2024   | 2023   | 2022   | 2021   |
|--------------------------------------------------------|---------------|--------|--------|--------|--------|
|                                                        | cents         | cents  | cents  | cents  | cents  |
| Net assets per share                                   | <b>57.09</b>  | 55.05  | 56.50  | 57.06  | 46.70  |
| Net tangible assets per share                          | <b>43.36</b>  | 41.55  | 45.08  | 45.15  | 28.25  |
| Earnings/(loss) per share                              | <b>1.98</b>   | (1.45) | 2.69   | 3.58   | 0.05   |
| Earnings/(loss) per share - excluding impairment & tax | <b>3.24</b>   | (1.58) | 3.71   | 6.01   | 0.44   |
| Share price                                            | <b>\$0.83</b> | \$0.72 | \$1.77 | \$2.02 | \$3.70 |

## Directors' Report

### For the Year Ended 30 June 2025

#### Remuneration report (audited)

The following table of benefits and payments details, in respect to the 2025 and 2024 financial years, the components of remuneration for each member of the key management personnel (KMP) of the Group.

#### Table of benefits and payments

|                                          | Short term employee benefits |          | Post employment benefits | LSL Benefits | Termination Benefits |                |
|------------------------------------------|------------------------------|----------|--------------------------|--------------|----------------------|----------------|
|                                          | cash salary fees             | bonus    | Superannuation           |              |                      | TOTAL\$        |
| Year Ended 30 June 2025                  | \$                           | \$       | \$                       | \$           | \$                   |                |
| <b>Non-Executive Directors</b>           |                              |          |                          |              |                      |                |
| Lev Mizikovsky                           | -                            | -        | -                        | -            | -                    | -              |
| Rade Dudurovic                           | 62,004                       | -        | -                        | -            | -                    | 62,004         |
| <b>Sub-total Non-Executive Directors</b> | <b>62,004</b>                | <b>-</b> | <b>-</b>                 | <b>-</b>     | <b>-</b>             | <b>62,004</b>  |
| <b>Executive Directors</b>               |                              |          |                          |              |                      |                |
| Geoff Acton                              | 292,250                      | -        | 6,530                    | 905          | -                    | 299,685        |
| <b>Sub-total Executive Directors</b>     | <b>292,250</b>               | <b>-</b> | <b>6,530</b>             | <b>905</b>   | <b>-</b>             | <b>299,685</b> |
|                                          | <b>354,254</b>               | <b>-</b> | <b>6,530</b>             | <b>905</b>   | <b>-</b>             | <b>361,689</b> |

|                                          | Short term employee benefits |          | Post employment benefits | LSL Benefits | Termination Benefits |                |
|------------------------------------------|------------------------------|----------|--------------------------|--------------|----------------------|----------------|
|                                          | cash salary fees             | bonus    | Superannuation           |              |                      | TOTAL\$        |
| Year Ended 30 June 2024                  | \$                           | \$       | \$                       | \$           | \$                   |                |
| <b>Non-Executive Directors</b>           |                              |          |                          |              |                      |                |
| Lev Mizikovsky                           | -                            | -        | -                        | -            | -                    | -              |
| Rade Dudurovic                           | 62,400                       | -        | -                        | -            | -                    | 62,400         |
| Linda Barr (Resigned 31 May 2024)        | 50,416                       | -        | -                        | -            | -                    | 50,416         |
| <b>Sub-total Non-Executive Directors</b> | <b>112,816</b>               | <b>-</b> | <b>-</b>                 | <b>-</b>     | <b>-</b>             | <b>112,816</b> |
| <b>Executive Directors</b>               |                              |          |                          |              |                      |                |
| Geoff Acton                              | 281,357                      | -        | 6,780                    | 846          | -                    | 288,983        |
| <b>Sub-total Executive Directors</b>     | <b>281,357</b>               | <b>-</b> | <b>6,780</b>             | <b>846</b>   | <b>-</b>             | <b>288,983</b> |
|                                          | <b>394,173</b>               | <b>-</b> | <b>6,780</b>             | <b>846</b>   | <b>-</b>             | <b>401,799</b> |

Remuneration for Mr. Acton's company secretarial services is set out on Note 26.

## Directors' Report

### For the Year Ended 30 June 2025

#### Remuneration report (audited)

##### Service Agreements

On appointment to the Board, all non-executive directors enter into a service agreement with the Group in the form of a letter of appointment. The letter summarises the Board policies and terms, including remuneration, relevant to the office of director.

The remuneration and other terms of employment for the Group's executives are formalised in service agreements and/or letters of employment, each of which provides for the executive's participation in any bonus or employee share schemes, plus other benefits and membership of approved professional or industry bodies.

On termination, Directors and other key management personnel are entitled to their statutory entitlements of accrued annual and long service leave, together with any superannuation benefits. No other termination benefits are payable.

Unless otherwise stated, service agreements and employment contracts do not provide for predetermined compensation values or the manner of payment. Compensation is determined in accordance with the general remuneration policy and outlined above. The manner of payment is determined on a case by case basis and is generally a mix of cash and non-cash benefits as considered appropriate by the Board.

##### Loans to Key Management Personnel

A loan was advanced to Geoff Acton on 8 September 2022 amounting to \$696,000. The funds were advanced to allow him to acquire off market shares in the Company. The balance at both 30 June 2024 and 30 June 2025 remains at \$696,000. The loan attracts an interest rate of 3.5%. Interest charged during the period and payable at the end of the period was \$24,360. Interest that would have been charged on an arm's length basis would be \$64,085. The shares acquired are to be held in escrow for 3 years.

##### Other services provided by Key Management Personnel

The company is provided with payroll, advisory and secretarial services by an entity associated with Geoff Acton on an arm's length basis. The total value of services provided for the year ended 30 June 2025 was \$219,437 (30 June 2024: \$175,347).

## Directors' Report

### For the Year Ended 30 June 2025

#### Remuneration report (audited)

#### Director's' shareholdings

|                                   | Balance at<br>beginning of<br>year | Granted as<br>remuneration | Exercised | Other changes    | Balance at the<br>end of year |
|-----------------------------------|------------------------------------|----------------------------|-----------|------------------|-------------------------------|
| <b>30 June 2025</b>               |                                    |                            |           |                  |                               |
| Directors                         |                                    |                            |           |                  |                               |
| Lev Mizikovsky                    | 39,811,098                         | -                          | -         | 598,165          | 40,409,263                    |
| Rade Dudurovic                    | 418,772                            | -                          | -         | -                | 418,772                       |
| Geoff Acton                       | 642,429                            | -                          | -         | -                | 642,429                       |
|                                   | <b>40,872,299</b>                  | <b>-</b>                   | <b>-</b>  | <b>598,165</b>   | <b>41,470,464</b>             |
| <b>30 June 2024</b>               |                                    |                            |           |                  |                               |
| Directors                         | -                                  | -                          | -         | -                | -                             |
| Lev Mizikovsky                    | 32,102,517                         | -                          | -         | 7,708,581        | 39,811,098                    |
| Rade Dudurovic                    | 418,772                            | -                          | -         | -                | 418,772                       |
| Linda Barr (Resigned 31 May 2024) | 4,000                              | -                          | -         | (4,000)          | -                             |
| Geoff Acton                       | 642,429                            | -                          | -         | -                | 642,429                       |
|                                   | <b>33,167,718</b>                  | <b>-</b>                   | <b>-</b>  | <b>7,704,581</b> | <b>40,872,299</b>             |

#### End of Audited Remuneration Report

This Directors' report, incorporating the remuneration report, is signed in accordance with a resolution of the Board of Directors.



Lev Mizikovsky  
Non-Executive Chairman

Dated: 29 August 2025

## Directors' Declaration

*The directors of the Company declare that*

1. *the financial statements and notes for the year ended 30 June 2025 are in accordance with the Corporations Act 2001 and:*
  - a. *comply with Accounting Standards, which, as stated in basis of preparation Note 1 to the financial statements, constitutes explicit and unreserved compliance with International Financial Reporting Standards (IFRS); and*
  - b. *give a true and fair view of the financial position and performance of the consolidated group;*
2. *the Chief Executive Officer have given the declarations required by Section 295A that:*
  - a. *the financial records of the Company for the financial year have been properly maintained in accordance with section 286 of the Corporations Act 2001;*
  - b. *the financial statements and notes for the financial year comply with the Accounting Standards; and*
  - c. *the financial statements and notes for the financial year give a true and fair view.*
3. *in the directors' opinion, there are reasonable grounds to believe that the Company will be able to pay its debts as and when they become due and payable.*
4. *The information disclosed in the attached consolidated entity disclosure statement is true and correct.*

This declaration is made in accordance with a resolution of the Board of Directors.



Lev Mizikovsky  
Non-Executive Chairman

Dated: 29 August 2025

## Lead Auditor's Independence Declaration under Section 307C of the Corporations Act 2001

### To the directors of Advance ZincTek Limited

As lead auditor for the audit of Advance ZincTek Limited for the year ended 30 June 2025, I declare that, to the best of my knowledge and belief, there have been:

- no contraventions of the auditor independence requirements as set out in the *Corporations Act 2001* in relation to the audit; and
- no contraventions of any applicable code of professional conduct in relation to the audit.

This declaration is in respect of Advance ZincTek Limited and the entities it controlled during the year.

William Buck

**William Buck (Qld)**  
ABN 21 559 713 106

M. Monaghan

**M J Monaghan**  
Partner  
Brisbane, 29 August 2025

## Consolidated Statement of Profit or Loss and Other Comprehensive Income For the Year Ended 30 June 2025

|                                                                    | Note | 2025<br>000's | 2024<br>000's |
|--------------------------------------------------------------------|------|---------------|---------------|
| Revenue                                                            | 5    | 11,639        | 9,320         |
| Other income                                                       | 5    | 676           | 684           |
| Raw materials and consumables used                                 |      | (4,927)       | (4,801)       |
| Employee benefits expense                                          |      | (1,637)       | (1,538)       |
| Superannuation                                                     |      | (257)         | (298)         |
| Amortisation charge                                                | 14   | (91)          | (62)          |
| Depreciation expense - Property, plant & equipment                 | 12   | (1,206)       | (1,262)       |
| Depreciation expense - right of use assets                         |      | (456)         | (513)         |
| Legal expense                                                      |      | (76)          | (120)         |
| Directors fees                                                     |      | (395)         | (403)         |
| Insurance fees                                                     |      | (184)         | (249)         |
| Rent expense                                                       |      | (24)          | (72)          |
| Lease interest expense                                             |      | (56)          | (89)          |
| Patent Renewal                                                     |      | (83)          | (62)          |
| Travel costs                                                       |      | (12)          | (14)          |
| Rates & taxes                                                      |      | (12)          | (6)           |
| Corporate costs                                                    |      | (171)         | (306)         |
| Consulting                                                         |      | (120)         | (211)         |
| Other operating expenses                                           |      | (584)         | (988)         |
| <b>Profit / (Loss) before income tax</b>                           |      | <b>2,024</b>  | <b>(990)</b>  |
| Income tax benefit (expense)                                       | 7    | (786)         | 87            |
| <b>Profit / (Loss) for the year</b>                                |      | <b>1,238</b>  | <b>(903)</b>  |
| <b>Other comprehensive income, net of income tax</b>               |      |               |               |
| Items that will not be reclassified subsequently to profit or loss |      | -             | -             |
| Items that will be reclassified subsequently to profit or loss     |      | -             | -             |
| <b>Other comprehensive income for the year, net of tax</b>         |      | <b>-</b>      | <b>-</b>      |
| <b>Total comprehensive income for the year</b>                     |      | <b>1,238</b>  | <b>(903)</b>  |
| <b>Profit attributable to:</b>                                     |      |               |               |
| Members of the parent entity                                       |      | 1,238         | (903)         |
| <b>Total comprehensive income attributable to:</b>                 |      |               |               |
| Members of the parent entity                                       |      | 1,238         | (903)         |
| <b>Earnings per share</b>                                          |      |               |               |
| Basic earnings per share (cents)                                   |      | 1.98 Cents    | (1.45) Cents  |
| Diluted earnings per share (cents)                                 |      | 1.98 Cents    | (1.45) Cents  |

The Consolidated Statement of Profit or Loss and Other Comprehensive Income should be read in conjunction with the accompanying notes

## Consolidated Statement of Financial Position As At 30 June 2025

|                                      | Note | 2025<br>000's | 2024<br>000's |
|--------------------------------------|------|---------------|---------------|
| <b>ASSETS</b>                        |      |               |               |
| <b>Current Assets</b>                |      |               |               |
| Cash and cash equivalents            | 8    | 629           | 163           |
| Trade and other receivables          | 9    | 3,277         | 2,358         |
| Inventories                          | 10   | 11,887        | 12,734        |
| Other assets                         | 11   | 629           | 446           |
| <b>Total Current Assets</b>          |      | <b>16,422</b> | <b>15,701</b> |
| <b>Non-Current Assets</b>            |      |               |               |
| Property, plant and equipment        | 12   | 11,617        | 11,941        |
| Right of use assets                  | 13   | 1,235         | 1,487         |
| Deferred tax assets                  | 15   | 5,652         | 5,943         |
| Development assets                   | 14   | 3,114         | 2,669         |
| <b>Total Non-Current Assets</b>      |      | <b>21,618</b> | <b>22,040</b> |
| <b>TOTAL ASSETS</b>                  |      | <b>38,040</b> | <b>37,741</b> |
| <b>LIABILITIES</b>                   |      |               |               |
| <b>Current Liabilities</b>           |      |               |               |
| Trade and other payables             | 16   | 691           | 1,110         |
| Lease liabilities                    |      | 418           | 415           |
| Provisions                           | 17   | 99            | 168           |
| Borrowings                           |      | -             | 320           |
| <b>Total Current Liabilities</b>     |      | <b>1,208</b>  | <b>2,013</b>  |
| <b>Non-Current Liabilities</b>       |      |               |               |
| Lease liabilities                    |      | 983           | 1,250         |
| Provisions                           | 17   | 80            | 98            |
| <b>Total Non-Current Liabilities</b> |      | <b>1,063</b>  | <b>1,348</b>  |
| <b>TOTAL LIABILITIES</b>             |      | <b>2,271</b>  | <b>3,361</b>  |
| <b>NET ASSETS</b>                    |      | <b>35,769</b> | <b>34,380</b> |
| <b>EQUITY</b>                        |      |               |               |
| Issued capital                       | 18   | 53,254        | 53,103        |
| Reserves                             | 19   | 1,519         | 1,519         |
| Accumulated losses                   |      | (19,004)      | (20,242)      |
| <b>TOTAL EQUITY</b>                  |      | <b>35,769</b> | <b>34,380</b> |

The Consolidated Statement of Financial Position should be read in conjunction with the accompanying notes.

## Consolidated Statement of Changes in Equity For the Year Ended 30 June 2025

2025

|                                                             | Issued<br>Capital<br>000's | Accumulated<br>Losses<br>000's | Foreign<br>Currency<br>Translation<br>Reserve<br>000's | Share Based<br>Payment<br>Reserve<br>000's | Total<br>000's |
|-------------------------------------------------------------|----------------------------|--------------------------------|--------------------------------------------------------|--------------------------------------------|----------------|
| <b>Balance at 1 July 2024</b>                               | <b>53,103</b>              | <b>(20,242)</b>                | <b>16</b>                                              | <b>1,503</b>                               | <b>34,380</b>  |
| Profit / (Loss) for the year                                | -                          | 1,238                          | -                                                      | -                                          | 1,238          |
| Other comprehensive income                                  | -                          | -                              | -                                                      | -                                          | -              |
| <b>Total comprehensive income for the year</b>              | <b>-</b>                   | <b>1,238</b>                   | <b>-</b>                                               | <b>-</b>                                   | <b>1,238</b>   |
| <b>Transactions with owners in their capacity as owners</b> |                            |                                |                                                        |                                            |                |
| Shares issued during the year                               | 151                        | -                              | -                                                      | -                                          | 151            |
| <b>Total Transaction with owners</b>                        | <b>151</b>                 | <b>-</b>                       | <b>-</b>                                               | <b>-</b>                                   | <b>151</b>     |
| <b>Balance at 30 June 2025</b>                              | <b>53,254</b>              | <b>(19,004)</b>                | <b>16</b>                                              | <b>1,503</b>                               | <b>35,769</b>  |

2024

|                                                             | Issued<br>Capital<br>000's | Accumulated<br>Losses<br>000's | Foreign<br>Currency<br>Translation<br>Reserve<br>000's | Share Based<br>Payment<br>Reserve<br>000's | Total<br>000's |
|-------------------------------------------------------------|----------------------------|--------------------------------|--------------------------------------------------------|--------------------------------------------|----------------|
| <b>Balance at 1 July 2023</b>                               | <b>53,103</b>              | <b>(19,339)</b>                | <b>16</b>                                              | <b>1,503</b>                               | <b>35,283</b>  |
| Profit / (Loss) for the year                                | -                          | (903)                          | -                                                      | -                                          | (903)          |
| Other comprehensive income                                  | -                          | -                              | -                                                      | -                                          | -              |
| <b>Total comprehensive income for the year</b>              | <b>-</b>                   | <b>(903)</b>                   | <b>-</b>                                               | <b>-</b>                                   | <b>(903)</b>   |
| <b>Transactions with owners in their capacity as owners</b> |                            |                                |                                                        |                                            |                |
| <b>Total Transaction with owners</b>                        | <b>-</b>                   | <b>-</b>                       | <b>-</b>                                               | <b>-</b>                                   | <b>-</b>       |
| <b>Balance at 30 June 2024</b>                              | <b>53,103</b>              | <b>(20,242)</b>                | <b>16</b>                                              | <b>1,503</b>                               | <b>34,380</b>  |

The Consolidated Statement of Changes in Equity should be read in conjunction with the accompanying notes.

## Consolidated Statement of Cash Flows For the Year Ended 30 June 2025

|                                                           | Note | 2025<br>000's     | 2024<br>000's     |
|-----------------------------------------------------------|------|-------------------|-------------------|
| <b>CASH FLOWS FROM OPERATING ACTIVITIES:</b>              |      |                   |                   |
| Receipts from customer (Inc.GST)                          |      | 11,099            | 11,015            |
| Payments to suppliers and employees (Inc.GST)             |      | (8,368)           | (8,687)           |
| Lease interest expense                                    |      | (56)              | (89)              |
| Net cash provided by/(used in) operating activities       | 24   | <u>2,675</u>      | <u>2,239</u>      |
| <b>CASH FLOWS FROM INVESTING ACTIVITIES:</b>              |      |                   |                   |
| Purchase of property, plant and equipment                 |      | (887)             | (1,451)           |
| Payment for development assets                            |      | (536)             | (757)             |
| Net cash used by investing activities                     |      | <u>(1,423)</u>    | <u>(2,208)</u>    |
| <b>CASH FLOWS FROM FINANCING ACTIVITIES:</b>              |      |                   |                   |
| (Decrease) / Increase in borrowings                       |      | (320)             | 320               |
| Repayment of lease liabilities                            |      | (466)             | (513)             |
| Net cash used by financing activities                     |      | <u>(786)</u>      | <u>(193)</u>      |
| Net increase/(decrease) in cash and cash equivalents held |      | 466               | (162)             |
| Cash and cash equivalents at beginning of year            | 8    | <u>163</u>        | <u>325</u>        |
| Cash and cash equivalents at end of financial year        | 8    | <u><u>629</u></u> | <u><u>163</u></u> |

The Consolidated Statement of Cash Flows should be read in conjunction with the accompanying notes.

## Notes to the Financial Statements

### For the Year Ended 30 June 2025

The financial report covers the consolidated financial statements and notes of Advance ZincTek Limited ("Company" or "ANO") and its controlled entities ('the Group'). Advance ZincTek Limited is a for-profit company limited by shares, incorporated and domiciled in Australia and whose shares are traded on the Australian Securities Exchange Limited.

Each of the entities within the Group prepare their financial statements based on the currency of the primary economic environment in which the entity operates (functional currency). The financial statements are presented in Australian dollars which is the parent entity's functional and presentation currency.

The financial report was authorised for issue by the Directors on 29 August 2025.

The separate financial statements and notes of the parent entity, Advance ZincTek Limited, have not been presented within this financial report as permitted by the Corporations Act 2001. Parent entity summary is included in note 4.

#### 1 Basis of preparation

The financial statements are general purpose financial statements that have been prepared in accordance with the Australian Accounting Standards and the *Corporations Act 2001*.

These financial statements and associated notes comply with International Financial Reporting Standards as issued by the International Accounting Standards Board.

##### *Historical cost convention*

The financial statements have been prepared under the historical cost convention.

#### 2 Material Accounting Policy Information

##### (a) Principles of consolidation

The consolidated financial statements include the financial position and performance of controlled entities from the date on which control is obtained until the date that control is lost.

Intragroup assets, liabilities, equity, income, expenses and cashflows relating to transactions between entities in the consolidated entity have been eliminated in full for the purpose of these financial statements.

Appropriate adjustments have been made to a controlled entity's financial position, performance and cash flows where the accounting policies used by that entity were different from those adopted by the consolidated entity. All controlled entities have a June financial year end.

##### **Subsidiaries**

Subsidiaries are all entities (including structured entities) over which the parent has control. Control is established when the parent is exposed to, or has rights to variable returns from its involvement with the entity and has the ability to affect those returns through its power to direct the relevant activities of the entity.

A list of controlled entities is contained in Note 20 to the financial statements.

##### (b) Income Tax

ANO and its wholly-owned Australian subsidiary has formed an income tax consolidation group under the tax consolidation regime. The Group notified the Australian Tax Office that it had formed an income tax consolidated group to apply from 1 July 2015.

## Notes to the Financial Statements

### For the Year Ended 30 June 2025

#### 2 Material Accounting Policy Information

##### (b) Income Tax

The tax expense recognised in the consolidated statement of profit or loss and other comprehensive income relates to current income tax expense plus deferred tax expense (being the movement in deferred tax assets and liabilities and unused tax losses during the year).

Current tax is the amount of income taxes payable (recoverable) in respect of the taxable profit (tax loss) for the year and is measured at the amount expected to be paid to (recovered from) the taxation authorities, using the tax rates (and tax laws) that have been enacted or substantively enacted by the end of the reporting period.

Deferred tax is provided on temporary differences which are determined by comparing the carrying amounts of tax bases of assets and liabilities to the carrying amounts in the consolidated financial statements.

Deferred tax assets and liabilities are measured at the tax rates that are expected to apply to the period when the asset is realised or the liability is settled, based on tax rates (and tax laws) that have been enacted or substantively enacted by the end of the reporting period.

Deferred tax consequences relating to a non-monetary asset carried at fair value are determined using the assumption that the carrying amount of the asset will be recovered through sale.

Deferred tax assets are recognised for all deductible temporary differences and unused tax losses to the extent that it is probable that taxable profit will be available against which the deductible temporary differences and losses can be utilised.

Current tax assets and liabilities are offset where there is a legally enforceable right to set off the recognised amounts and there is an intention either to settle on a net basis or to realise the asset and settle the liability simultaneously.

Deferred tax assets and liabilities are offset where there is a legal right to set off current tax assets against current tax liabilities and the deferred tax assets and the deferred tax liabilities relate to income taxes levied by the same taxation authority on either the same taxable entity or different taxable entities which intend either to settle current tax liabilities and assets on a net basis, or to realise the assets and settle the liabilities simultaneously in each future period in which significant amounts of deferred tax liabilities or assets are expected to be settled or recovered.

Current and deferred tax is recognised as income or an expense and included in profit or loss for the period except where the tax arises from a transaction which is recognised in other comprehensive income or equity, in which case the tax is recognised in other comprehensive income or equity respectively.

##### (c) Comparative Amounts

Comparatives are consistent with prior years, unless otherwise stated.

Where a material change in comparatives has also affected the opening retained earnings previously presented in a comparative period, an opening consolidated statement of financial position at the earliest date of the comparative period has been presented.

When impracticable to determine the period to which an error relates, the opening balances of assets, liabilities and equity for the earliest period for which retrospective restatement is practicable are restated.

## Notes to the Financial Statements

### For the Year Ended 30 June 2025

#### 2 Material Accounting Policy Information

##### (d) Inventories

Inventories are measured at the lower of cost and net realisable value. Costs incurred in bringing each product to its present location and condition are accounted for as follows:

###### *Raw Materials*

Purchase cost is determined using the first-in-first-out basis and is net of any rebates and discounts received.

###### *Finished Goods and Work-in-progress*

Cost of direct material and labour and a proportion of overheads based on normal operating capacity.

Net realisable value is the estimated selling price in the ordinary course of business, less the estimated costs of completion and the costs necessary to make the sale. Costs are assigned in a first-in-first-out basis. Net realisable value is estimated using the most reliable evidence available at the reporting date and inventory is written down through an obsolescence provision if necessary.

##### (e) Property, plant and equipment

Classes of property, plant and equipment are measured using the cost model as specified below.

Where the cost model is used, the asset is carried at its cost less any accumulated depreciation and any impairment losses. Costs include purchase price, other directly attributable costs and the initial estimate of the costs of dismantling and restoring the asset, where applicable.

###### **Plant and equipment**

Plant and equipment are measured using the cost model.

###### **Depreciation**

Property, plant and equipment, excluding freehold land, is depreciated on a straight-line basis over the assets useful life to the Group, commencing when the asset is ready for use.

Leased assets and leasehold improvements are amortised over the shorter of either the unexpired period of the lease or their estimated useful life.

The estimated useful lives used for each class of depreciable asset are shown below:

| <b>Fixed asset class</b> | <b>Useful life</b> |
|--------------------------|--------------------|
| Plant and Equipment      | 10 - 20 years      |
| Motor Vehicles           | 5 years            |

At the end of each annual reporting period, the depreciation method, useful life and residual value of each asset is reviewed. Any revisions are accounted for prospectively as a change in estimate.

When an asset is disposed, the gain or loss is calculated by comparing proceeds received with its carrying amount and is taken to profit or loss.

## Notes to the Financial Statements

### For the Year Ended 30 June 2025

#### 2 Material Accounting Policy Information

##### (f) Research and development costs

Research costs are expensed in the period in which they are incurred. Development costs are capitalised when it is probable that the project will be a success considering its commercial and technical feasibility; the consolidated entity is able to use or sell the asset; the consolidated entity has sufficient resources and intent to complete the development; and its costs can be measured reliably.

##### Development Assets

The development of end formulation products comprises a number of phases including initial development, customer testing and feedback, testing processes including stability and SPF testing and regulatory approvals in order to be "shelf-ready" and capable of being sold. These costs are capitalised to work-in-progress and once the products are fully approved, these work-in-progress amounts will be transferred to end formulation assets.

The expenditure capitalised includes the cost of materials, direct labour and overhead costs that are directly attributable to preparing the asset for its intended use and capitalised borrowing costs.

Capitalised development costs are measured at cost less accumulated amortisation and accumulated impairment losses.

##### Amortisation

Amortisation is recognised in profit or loss on a straight-line basis over the estimated useful lives of intangible assets, other than goodwill, from the date that they are available for use.

Amortisation methods, useful lives and residual values are reviewed at each reporting date and adjusted if appropriate.

Development assets have a finite life and are amortised on a systematic basis matched to the future economic benefits over the useful life of the project which is generally 10 years.

##### (g) Employee benefits

Provision is made for the Group's liability for employee benefits arising from services rendered by employees to the end of the reporting period. Employee benefits that are expected to be wholly settled within one year have been measured at the amounts expected to be paid when the liability is settled.

Employee benefits expected to be settled more than one year after the end of the reporting period have been measured at the present value of the estimated future cash outflows to be made for those benefits. In determining the liability, consideration is given to employee wage increases and the probability that the employee may satisfy vesting requirements. Cashflows are discounted using market yields on national government bonds, with terms to maturity that match the expected timing of cashflows. Changes in the measurement of the liability are recognised in profit or loss.

##### (h) Provisions

Provisions are recognised when the Group has a legal or constructive obligation, as a result of past events, for which it is probable that an outflow of economic benefits will result and that outflow can be reliably measured.

Provisions are measured at the present value of management's best estimate of the outflow required to settle the obligation at the end of the reporting period. The discount rate used is a pre-tax rate that reflects current market assessments of the time value of money and the risks specific to the liability. The increase in the provision due to the unwinding of the discount is taken to finance costs in the consolidated statement of profit or loss and other comprehensive income.

## Notes to the Financial Statements

### For the Year Ended 30 June 2025

#### 2 Material Accounting Policy Information

##### (h) Provisions

Provisions recognised represent the best estimate of the amounts required to settle the obligation at the end of the reporting period.

##### (i) Issued capital

Ordinary shares are classified as equity. Incremental costs directly attributable to the issue of ordinary shares and share options which vest immediately are recognised as a deduction from equity, net of any tax effects.

##### (j) Right-of-use assets

A right-of-use asset is recognised at the commencement date of a lease. The right-of-use asset is measured at cost, which comprises the initial amount of the lease liability, adjusted for, as applicable, any lease payments made at or before the commencement date net of any lease incentives received, any initial direct costs incurred, and, except where included in the cost of inventories, an estimate of costs expected to be incurred for dismantling and removing the underlying asset, and restoring the site or asset.

Right-of-use assets are depreciated on a straight-line basis over the unexpired period of the lease or the estimated useful life of the asset, whichever is the shorter. Where the consolidated entity expects to obtain ownership of the leased asset at the end of the lease term, the depreciation is over its estimated useful life. Right-of-use assets are subject to impairment or adjusted for any remeasurement of lease liabilities.

The consolidated entity has elected not to recognise a right-of-use asset and corresponding lease liability for short-term leases with terms of 12 months or less and leases of low-value assets. Lease payments on these assets are expensed to profit or loss as incurred.

##### (k) Lease liabilities

A lease liability is recognised at the commencement date of a lease. The lease liability is initially recognised at the present value of the lease payments to be made over the term of the lease, discounted using the interest rate implicit in the lease or, if that rate cannot be readily determined, the consolidated entity's incremental borrowing rate. Lease payments comprise of fixed payments less any lease incentives receivable, variable lease payments that depend on an index or a rate, amounts expected to be paid under residual value guarantees, exercise price of a purchase option when the exercise of the option is reasonably certain to occur, and any anticipated termination penalties. The variable lease payments that do not depend on an index or a rate are expensed in the period in which they are incurred.

Lease liabilities are measured at amortised cost using the effective interest method. The carrying amounts are remeasured if there is a change in the following: future lease payments arising from a change in an index or a rate used; residual guarantee; lease term; certainty of a purchase option and termination penalties. When a lease liability is remeasured, an adjustment is made to the corresponding right-of-use asset, or to profit or loss if the carrying amount of the right-of-use asset is fully written down.

##### (l) Revenue and other income

Revenue is recognised at an amount that reflects the consideration to which the consolidated entity is expected to be entitled in exchange for transferring goods or services to a customer.

Variable consideration within the transaction price, if any, reflects concessions provided to the customer such

## Notes to the Financial Statements

### For the Year Ended 30 June 2025

#### 2 Material Accounting Policy Information

##### (l) Revenue and other income

as discounts, rebates and refunds, any potential bonuses receivable from the customer and any other contingent events. Such estimates are determined using either the 'expected value' or 'most likely amount' method. The measurement of variable consideration is subject to a constraining principle whereby revenue will only be recognised to the extent that it is highly probable that a significant reversal in the amount of cumulative revenue recognised will not occur. The measurement constraint continues until the uncertainty associated with the variable consideration is subsequently resolved. Amounts received that are subject to the constraining principle are recognised as a refund liability. Revenue arises mainly from the sale of proprietary advanced material products.

To determine whether to recognise revenue, the Group follows a 5 step process:

1. Identifying the contract with a customer
2. Identifying the performance obligations
3. Determining the transaction price
4. Allocating the transaction price to the performance obligations
5. Recognising revenue when/as performance obligation(s) are satisfied.

Revenue is recognised either at a point in time or over time, when (or as) the Group satisfies performance obligations by transferring the promised goods or services to its customers.

##### Revenue from sale of proprietary advanced material products

Revenue from sale of proprietary advanced material products is recognised when or as the Group has transferred control of the assets to the customer. Invoices for goods transferred are due upon receipt by the customer. Control transfers at the point in time the customer takes undisputed delivery of the goods.

##### Other income

Other income is recognised on an accruals basis when the Group is entitled to it.

##### (m) Finance costs

Borrowing costs that are directly attributable to the acquisition, construction or production of a qualifying asset are capitalised as part of the cost of that asset.

All other borrowing costs are recognised as an expense in the period in which they are incurred.

## Notes to the Financial Statements

### For the Year Ended 30 June 2025

#### 2 Material Accounting Policy Information

##### (n) Foreign currency transactions and balances

###### Transaction and balances

Foreign currency transactions are recorded at the spot rate on the date of the transaction.

At the end of the reporting period:

- Foreign currency monetary items are translated using the closing rate;
- Non-monetary items that are measured at historical cost are translated using the exchange rate at the date of the transaction; and
- Non-monetary items that are measured at fair value are translated using the rate at the date when fair value was determined.

For the purpose of presenting these consolidated financial statements, the assets and liabilities of the Group's foreign operations are translated into Australian dollars using exchange rates prevailing at the end of the reporting period. Income and expense items are translated at the average exchange rates for the period, unless exchange rates fluctuated significantly during the period, in which case the rates at the dates of the transaction are used.

Exchange differences arising on the settlement of monetary items or on translating monetary items at rates different from those at which they were translated on initial recognition or in prior reporting periods are recognised through profit or loss, except where they relate to an item of other comprehensive income or whether they are deferred in equity as qualifying hedges.

##### (o) Share based payments

Equity-settled share-based compensation benefits are provided to employees.

Equity-settled transactions are awards of shares, or options over shares, that are provided to employees in exchange for the rendering of services.

The cost of equity-settled transactions are measured at fair value on grant date. Fair value is independently determined using either the Black-Scholes option pricing model that takes into account the exercise price, the term of the option, the impact of dilution, the share price at grant date and expected price volatility of the underlying share, the expected dividend yield and the risk free interest rate for the term of the option, together with non-vesting conditions that do not determine whether the consolidated entity receives the services that entitle the employees to receive payment. No account is taken of any other vesting conditions.

The cost of equity-settled transactions are recognised as an expense with a corresponding increase in equity over the vesting period. The cumulative charge to profit or loss is calculated based on the grant date fair value of the award, the best estimate of the number of awards that are likely to vest and the expired portion of the vesting period. The amount recognised in profit or loss for the period is the cumulative amount calculated at each reporting date less amounts already recognised in previous periods.

If equity-settled awards are modified, as a minimum an expense is recognised as if the modification has not been made. An additional expense is recognised, over the remaining vesting period, for any modification that increases the total fair value of the share-based compensation benefit as at the date of modification.

If the non-vesting condition is within the control of the consolidated entity or employee, the failure to satisfy the condition is treated as a cancellation. If the condition is not within the control of the consolidated entity or employee and is not satisfied during the vesting period, any remaining expense for the award is recognised over the remaining vesting period, unless the award is forfeited.

## Notes to the Financial Statements

### For the Year Ended 30 June 2025

#### 2 Material Accounting Policy Information

##### (o) Share based payments

If equity-settled awards are cancelled, it is treated as if it has vested on the date of cancellation, and any remaining expense is recognised immediately. If a new replacement award is substituted for the cancelled award, the cancelled and new award is treated as if they were a modification.

An Employee Share Plan ( 'Plan' ) has been established to enable officers, staff and contractors to participate in the capital growth of the Company. The Group follows this by allowing all Eligible Employees of the Group to be issued shares in the Company.

Restriction on disposal - A participant may not dispose of, deal in, or grant a security interest over, any interest in a share issued under the Plan until the earlier of

- i. the end of the period of three years commencing on the date of the issue of that share
- ii. the date on which the participant is no longer employed by a Group company; and
- iii. the end of any other period determined by the Board in accordance with relevant law.

Shares to rank pari passu - Shares issued under the Plan will rank equally in all respects with ordinary shares in the company for the time being on issue except for any rights attached to the shares by reference to a record date prior to the date of issue.

The Plan is in compliance with the Corporations Act and Listing Rules of ASX as amended or waived from time to time.

##### (p) Trade and other receivables

Trade receivables are initially recognised at fair value and subsequently measured at amortised cost using the effective interest method, less any allowance for expected credit losses. Trade receivables are generally due for settlement within 30 days.

The consolidated entity has applied the simplified approach to measuring expected credit losses, which uses a lifetime expected loss allowance. To measure the expected credit losses, trade receivables have been grouped based on days overdue.

Other receivables are recognised at amortised cost, less any allowance for expected credit losses.

##### (q) Operating segments

Operating segments are presented using the 'management approach', where the information presented is on the same basis as the internal reports provided to the Chief Operating Decision Makers ('CODM'). The CODM is responsible for the allocation of resources to operating segments and assessing their performance.

##### (r) Current and non-current classification

Assets and liabilities are presented in the statement of financial position based on current and non-current classification.

An asset is classified as current when: it is either expected to be realised or intended to be sold or consumed in the consolidated entity's normal operating cycle; it is held primarily for the purpose of trading; it is expected to be realised within 12 months after the reporting period; or the asset is cash or cash equivalent unless restricted from being exchanged or used to settle a liability for at least 12 months after the reporting period. All other assets are classified as non-current.

## Notes to the Financial Statements

### For the Year Ended 30 June 2025

#### 2 Material Accounting Policy Information

##### (r) Current and non-current classification

A liability is classified as current when: it is either expected to be settled in the consolidated entity's normal operating cycle; it is held primarily for the purpose of trading; it is due to be settled within 12 months after the reporting period; or there is no unconditional right to defer the settlement of the liability for at least 12 months after the reporting period. All other liabilities are classified as non-current.

Deferred tax assets and liabilities are always classified as non-current.

##### (s) Impairment of non-financial assets

Goodwill and other intangible assets that have an indefinite useful life are not subject to amortisation and are tested annually for impairment, or more frequently if events or changes in circumstances indicate that they might be impaired. Other non-financial assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. An impairment loss is recognised for the amount by which the asset's carrying amount exceeds its recoverable amount.

Recoverable amount is the higher of an asset's fair value less costs of disposal and value-in-use. The value-in-use is the present value of the estimated future cash flows relating to the asset using a pre-tax discount rate specific to the asset or cash-generating unit to which the asset belongs. Assets that do not have independent cash flows are grouped together to form a cash-generating unit.

##### (t) Adoption of new and revised accounting standards

The consolidated entity has adopted all of the new or amended Accounting Standards and Interpretations issued by the Australian Accounting Standards Board ('AASB') that are mandatory for the current reporting period. These did not have a material impact on the consolidated entity.

Any new or amended Accounting Standards or Interpretations that are not yet mandatory have not been early adopted.

#### 3 Critical Accounting Estimates and Judgments

The directors make estimates and judgements during the preparation of these financial statements regarding assumptions about current and future events affecting transactions and balances.

These estimates and judgements are based on the best information available at the time of preparing the financial statements, however as additional information is known then the actual results may differ from the estimates.

The significant estimates and judgements made have been described below.

##### Key estimates - inventories

Inventories are valued at the lower of cost and net realisable value. The Group assesses net realisable value by reference to the current and expected future selling price of its products. Where the consumption of certain inventory balances for future sales is not reasonably assured, the Group recognises an expense in the current year.

## Notes to the Financial Statements

### For the Year Ended 30 June 2025

#### 3 Critical Accounting Estimates and Judgments

##### Key estimates - development costs

Development expenditure incurred on an individual project is carried forward (capitalised) when management considers that its future recoverability can reasonably be regarded as assured.

Expenditure on research activities is recognised as an expense in the period in which it is incurred. An internally-generated intangible asset arising from development (or from the development phase of an internal project) is recognised if, and only if, all of the following have been demonstrated:

- the technical feasibility of completing the intangible asset so that it will be available for use or sale;
- the intention to complete the intangible asset and use or sell it;
- the ability to use or sell the intangible asset;
- how the intangible asset will generate probable future economic benefits;
- the availability of adequate technical, financial and other resources to complete the development and to use or sell the intangible asset; and
- the ability to measure reliably the expenditure attributable to the intangible asset during its development.

The amount initially recognised for internally generated intangible assets is the sum of the expenditure incurred from the date when the intangible asset first meets recognition criteria listed above. Where no internally generated intangible asset can be recognised, expenditure is recognised in profit or loss in the period in which it is incurred.

Subsequent to initial recognition, internally generated intangible assets are reported at cost less accumulated amortisation and accumulated impairment losses, on the same basis as intangible assets that are acquired separately.

## Notes to the Financial Statements

### For the Year Ended 30 June 2025

#### 4 Parent entity

The following information has been extracted from the books and records of the parent, Advance ZincTek Limited and has been prepared in accordance with Accounting Standards.

The financial information for the parent entity, Advance ZincTek Limited has been prepared on the same basis as the consolidated financial statements except as disclosed below.

##### *Investment in subsidiaries*

Investments in subsidiaries are accounted for at cost in the financial statements of the parent entity.

|                                                                   | 2025<br>000's | 2024<br>000's |
|-------------------------------------------------------------------|---------------|---------------|
| <b>Statement of Financial Position</b>                            |               |               |
| Assets                                                            |               |               |
| Current assets                                                    | 16,422        | 15,701        |
| Non-current assets                                                | 21,618        | 22,040        |
| Total Assets                                                      | 38,040        | 37,741        |
| Liabilities                                                       |               |               |
| Current liabilities                                               | 1,208         | 2,013         |
| Non-current liabilities                                           | 1,063         | 1,348         |
| Total Liabilities                                                 | 2,271         | 3,361         |
| Equity                                                            |               |               |
| Issued capital                                                    | 53,254        | 53,103        |
| Retained earnings                                                 | (19,004)      | (20,242)      |
| Reserves                                                          | 1,519         | 1,519         |
| Total Equity                                                      | 35,769        | 34,380        |
| <b>Statement of Profit or Loss and Other Comprehensive Income</b> |               |               |
| Total profit or loss for the year                                 | 1,238         | (903)         |
| <b>Total comprehensive income</b>                                 | 1,238         | (903)         |

#### **Guarantees**

The parent entity did not have any guarantees as at 30 June 2025 or 30 June 2024.

#### **Contingent liabilities**

The parent entity did not have any contingent liabilities as at 30 June 2025 or 30 June 2024.

## Notes to the Financial Statements

### For the Year Ended 30 June 2025

#### 5 Revenue and Other Income

##### Revenue from continuing operations

|                                         | 2025<br>000's | 2024<br>000's |
|-----------------------------------------|---------------|---------------|
| Sales revenue                           |               |               |
| - Sale of ZinClear                      | 11,100        | 7,830         |
| - Sale of White Sapphire                | 150           | 1,020         |
| - Sale of Sunscreen Products            | 389           | 470           |
| <b>Total Revenue</b>                    | <b>11,639</b> | <b>9,320</b>  |
| Other Income                            |               |               |
| - R&D tax incentive                     | 495           | 515           |
| - Interest                              | 87            | 80            |
| - Gain / (Loss) on exchange differences | 62            | (28)          |
| - Other income                          | 32            | 117           |
| <b>Total Other income</b>               | <b>676</b>    | <b>684</b>    |

#### 6 Auditors' Remuneration

|                                                                                                     | 2025<br>\$    | 2024<br>\$    |
|-----------------------------------------------------------------------------------------------------|---------------|---------------|
| Remuneration of the auditor of the parent entity for auditing or reviewing the financial statements |               |               |
| - William Buck (QLD)                                                                                | 72,800        | 72,600        |
| <b>Total</b>                                                                                        | <b>72,800</b> | <b>72,600</b> |

## Notes to the Financial Statements

### For the Year Ended 30 June 2025

#### 7 Income Tax Expense

(a) The major components of tax expense (income) comprise:

|                                                                      | 2025<br>000's | 2024<br>000's |
|----------------------------------------------------------------------|---------------|---------------|
| Current tax expense / (benefit)                                      |               |               |
| Current income tax                                                   | -             | -             |
| Adjustments recognised for current tax of prior periods              | -             | -             |
| Deferred tax expense                                                 |               |               |
| Relating to the origination and reversal of temporary differences    | 291           | (602)         |
| Adjustments recognised for impact of R&D tax incentive of prior year | 495           | 515           |
| <b>Income tax expense / (benefit) for continuing operations</b>      | <b>786</b>    | <b>(87)</b>   |
| <b>Total income tax expense / (benefit)</b>                          | <b>786</b>    | <b>(87)</b>   |

(b) Reconciliation of income tax to accounting profit:

|                                                                                             | 2025<br>000's | 2024<br>000's |
|---------------------------------------------------------------------------------------------|---------------|---------------|
| Profit / (Loss) before income tax from continuing operations                                | 2,024         | (990)         |
| Prima facie income tax expense/(benefit) at the statutory income tax rate of 30% (2024:30%) | 607           | (297)         |
| Tax effect of:                                                                              |               |               |
| - Permanent differences                                                                     | (316)         | (350)         |
| Adjustments in respect of current income tax of previous years:                             |               |               |
| Adjustment recognised for impact of R&D tax incentive of prior years                        | 495           | 515           |
| Other                                                                                       | -             | 45            |
| <b>Income tax expense</b>                                                                   | <b>786</b>    | <b>(87)</b>   |

#### 8 Cash and Cash Equivalents

|                          | 2025<br>000's | 2024<br>000's |
|--------------------------|---------------|---------------|
| Cash at bank and on hand | 629           | 163           |
|                          | <b>629</b>    | <b>163</b>    |

## Notes to the Financial Statements

### For the Year Ended 30 June 2025

#### 9 Trade and Other Receivables

|                                                  | 2025<br>000's | 2024<br>000's |
|--------------------------------------------------|---------------|---------------|
| CURRENT                                          |               |               |
| Trade receivables                                | 2,148         | 1,091         |
|                                                  | <b>2,148</b>  | 1,091         |
| Loans to directors, managers and employees       | 1,068         | 1,001         |
| Related party receivables                        | 36            | -             |
| Other receivables                                | 25            | 266           |
| <b>Total current trade and other receivables</b> | <b>3,277</b>  | <b>2,358</b>  |

#### (a) Aged analysis

The ageing analysis of receivables is as follows:

|                 | 2025<br>000's | 2024<br>000's |
|-----------------|---------------|---------------|
| 0-30 days       | 1,041         | 426           |
| 31-60 days      | 995           | 245           |
| 61days and over | 112           | 420           |
|                 | <b>2,148</b>  | 1,091         |

The carrying value of trade receivables is considered a reasonable approximation of fair value due to the short-term nature of the balances.

The maximum exposure to credit risk at the reporting date is the fair value of each class of receivable in the financial statements. Refer to Note 27(b) for further details of credit risk management.

## Notes to the Financial Statements

### For the Year Ended 30 June 2025

#### 10 Inventories

|                               | 2025<br>000's | 2024<br>000's |
|-------------------------------|---------------|---------------|
| CURRENT                       |               |               |
| At cost:                      |               |               |
| Raw materials and consumables | 6,247         | 6,833         |
| Finished goods                | 5,743         | 5,964         |
| Provision for impairment      | (103)         | (63)          |
|                               | <u>11,887</u> | <u>12,734</u> |

Write downs of inventories to net realisable value during the year were \$ NIL (2024: \$ NIL).

#### 11 Other Assets

|                         | 2025<br>000's | 2024<br>000's |
|-------------------------|---------------|---------------|
| CURRENT                 |               |               |
| Prepayments             | 131           | 129           |
| Deposits with suppliers | 498           | 317           |
|                         | <u>629</u>    | <u>446</u>    |

As part of the trading requirements of overseas suppliers, the Group pays deposits in advance to suppliers for future supply of inventories.

## Notes to the Financial Statements

### For the Year Ended 30 June 2025

#### 12 Property, plant and equipment

|                                               | 2025<br>000's | 2024<br>000's |
|-----------------------------------------------|---------------|---------------|
| <b>Motor Vehicles</b>                         |               |               |
| Motor Vehicles                                | 326           | 327           |
| Accumulated depreciation                      | (249)         | (193)         |
| <b>Total Motor Vehicles</b>                   | <b>77</b>     | <b>134</b>    |
| <b>Office eqpt, Furn &amp; Fixtures</b>       |               |               |
| Furniture, Fixtures and Fittings              | 963           | 921           |
| Accumulated depreciation                      | (875)         | (835)         |
| <b>Total Office eqpt, Furn &amp; Fixtures</b> | <b>88</b>     | <b>86</b>     |
| <b>R &amp; D eqpt, Quality Eqpt</b>           |               |               |
| At cost                                       | 786           | 851           |
| Accumulated depreciation                      | (551)         | (567)         |
| <b>Total R &amp; D eqpt, Quality Eqpt</b>     | <b>235</b>    | <b>284</b>    |
| <b>Production Plant</b>                       |               |               |
| At cost                                       | 10,036        | 10,217        |
| Accumulated depreciation                      | (4,605)       | (4,486)       |
| <b>Total Production Plant</b>                 | <b>5,431</b>  | <b>5,731</b>  |
| <b>Leasehold Improvements</b>                 |               |               |
| At cost                                       | 6,160         | 5,652         |
| Accumulated depreciation                      | (1,533)       | (1,179)       |
| <b>Total Leasehold Improvements</b>           | <b>4,627</b>  | <b>4,473</b>  |
| <b>Laboratory</b>                             |               |               |
| At cost                                       | 1,735         | 1,654         |
| Accumulated depreciation                      | (611)         | (460)         |
| <b>Total Laboratory</b>                       | <b>1,124</b>  | <b>1,194</b>  |
| <b>Clean Room</b>                             |               |               |
| At cost                                       | 56            | 56            |
| Accumulated depreciation                      | (21)          | (17)          |
| <b>Total Clean Room</b>                       | <b>35</b>     | <b>39</b>     |
| <b>Total property, plant and equipment</b>    | <b>11,617</b> | <b>11,941</b> |

## Notes to the Financial Statements

### For the Year Ended 30 June 2025

#### 12 Property, plant and equipment

##### (a) Movements in carrying amounts of property, plant and equipment

Movement in the carrying amounts for each class of property, plant and equipment between the beginning and the end of the current financial year:

|                                       | Office eqpt,<br>Furn & Fixtures<br>000's | Motor<br>Vehicles<br>000's | R & D eqpt,<br>Quality Eqpt<br>000's | Production<br>Plant<br>000's | Leasehold<br>Improvts<br>000's | Lab Assets<br>000's | Clean Room<br>000's | Total<br>000's |
|---------------------------------------|------------------------------------------|----------------------------|--------------------------------------|------------------------------|--------------------------------|---------------------|---------------------|----------------|
| <b>Year ended 30 June 2025</b>        |                                          |                            |                                      |                              |                                |                     |                     |                |
| Balance at the beginning of year      | 86                                       | 134                        | 284                                  | 5,731                        | 4,473                          | 1,194               | 39                  | 11,941         |
| Additions                             | 42                                       | -                          | -                                    | 240                          | 527                            | 81                  | -                   | 890            |
| Disposals - written down value        | -                                        | -                          | (8)                                  | -                            | -                              | -                   | -                   | (8)            |
| Depreciation expense                  | (40)                                     | (57)                       | (41)                                 | (540)                        | (373)                          | (151)               | (4)                 | (1,206)        |
| <b>Balance at the end of the year</b> | <b>88</b>                                | <b>77</b>                  | <b>235</b>                           | <b>5,431</b>                 | <b>4,627</b>                   | <b>1,124</b>        | <b>35</b>           | <b>11,617</b>  |

|                                       | Office eqpt,<br>Furn & Fixtures<br>000's | Motor<br>Vehicles<br>000's | R & D eqpt,<br>Quality Eqpt<br>000's | Production<br>Plant<br>000's | Leasehold<br>Improvts<br>000's | Lab Assets<br>000's | Clean Room<br>000's | Total<br>000's |
|---------------------------------------|------------------------------------------|----------------------------|--------------------------------------|------------------------------|--------------------------------|---------------------|---------------------|----------------|
| <b>Year ended 30 June 2024</b>        |                                          |                            |                                      |                              |                                |                     |                     |                |
| Balance at the beginning of year      | 128                                      | 81                         | 316                                  | 6,005                        | 4,218                          | 1,210               | 46                  | 12,004         |
| Additions                             | 2                                        | 114                        | 8                                    | 451                          | 752                            | 125                 | -                   | 1,451          |
| Disposals - written down value        | -                                        | (13)                       | -                                    | (116)                        | (124)                          | -                   | -                   | (253)          |
| Depreciation expense                  | (44)                                     | (48)                       | (40)                                 | (609)                        | (373)                          | (141)               | (8)                 | (1,262)        |
| <b>Balance at the end of the year</b> | <b>86</b>                                | <b>134</b>                 | <b>284</b>                           | <b>5,731</b>                 | <b>4,473</b>                   | <b>1,194</b>        | <b>39</b>           | <b>11,941</b>  |

## Notes to the Financial Statements

### For the Year Ended 30 June 2025

#### 13 Right of use assets

|                                   | 2025<br>000's | 2024<br>000's |
|-----------------------------------|---------------|---------------|
| Land and buildings - Right of use | 3,143         | 3,499         |
| Accumulated depreciation          | (1,908)       | (2,012)       |
|                                   | <u>1,235</u>  | <u>1,487</u>  |

The consolidated entity leases land and buildings for its offices, warehouses and retail outlets under agreements of between 1 to 3 years with, in some cases, options to extend. The leases have various escalation clauses. On renewal, the terms of the leases are renegotiated.

#### 14 Development Assets

|                                    | 2025<br>000's       | 2024<br>000's       |
|------------------------------------|---------------------|---------------------|
| Development Costs Work-in-Progress | 929                 | 1,248               |
| <b>ZinXation</b>                   |                     |                     |
| At cost                            | 783                 | 365                 |
| Accumulated amortisation           | (132)               | (107)               |
| <b>Total ZinXation</b>             | <u>651</u>          | <u>258</u>          |
| <b>Patented Dispersions</b>        |                     |                     |
| At cost                            | 1,417               | 980                 |
| Accumulated amortisation           | (95)                | (38)                |
| <b>Total Patented Dispersions</b>  | <u>1,322</u>        | <u>942</u>          |
| <b>Formulations</b>                |                     |                     |
| At cost                            | 383                 | 383                 |
| Accumulated amortisation           | (171)               | (162)               |
| <b>Total Formulations</b>          | <u>212</u>          | <u>221</u>          |
| <b>Total Development assets</b>    | <u><u>3,114</u></u> | <u><u>2,669</u></u> |

## Notes to the Financial Statements

### For the Year Ended 30 June 2025

#### 14 Development Assets

##### (a) Movements in carrying amounts of Development assets

|                                      | Development costs – Work in Progress<br>000's | ZinXation<br>000's | Patented Dispersions<br>000's | Formulations<br>000's | Total<br>000's |
|--------------------------------------|-----------------------------------------------|--------------------|-------------------------------|-----------------------|----------------|
| <b>Year ended 30 June 2025</b>       |                                               |                    |                               |                       |                |
| Balance at the beginning of the year | 1,248                                         | 258                | 942                           | 221                   | 2,669          |
| Additions                            | 536                                           | -                  | -                             | -                     | 536            |
| Transfer between asset classes       | (855)                                         | 418                | 437                           | -                     | -              |
| Amortisation expense                 | -                                             | (25)               | (57)                          | (9)                   | (91)           |
| <b>Balance at the end of year</b>    | <b>929</b>                                    | <b>651</b>         | <b>1,322</b>                  | <b>212</b>            | <b>3,114</b>   |

|                                      | Development costs – Work in Progress<br>000's | ZinXation<br>000's | Patented Dispersions<br>000's | Formulations<br>000's | Total<br>000's |
|--------------------------------------|-----------------------------------------------|--------------------|-------------------------------|-----------------------|----------------|
| <b>Year ended 30 June 2024</b>       |                                               |                    |                               |                       |                |
| Balance at the beginning of the year | 1,472                                         | 283                | -                             | 221                   | 1,976          |
| Additions                            | 622                                           | -                  | 133                           | -                     | 755            |
| Transfer between asset classes       | (846)                                         | -                  | 846                           | -                     | -              |
| Amortisation expense                 | -                                             | (25)               | (37)                          | -                     | (62)           |
| <b>Balance at the end of year</b>    | <b>1,248</b>                                  | <b>258</b>         | <b>942</b>                    | <b>221</b>            | <b>2,669</b>   |

## Notes to the Financial Statements

### For the Year Ended 30 June 2025

#### 15 Tax assets and liabilities

##### (a) Deferred tax assets

Deferred tax assets balance comprises temporary differences attributable to:

|                                                             | 2025<br>000's | 2024<br>000's |
|-------------------------------------------------------------|---------------|---------------|
| <b>Amounts recognised in profit and loss</b>                |               |               |
| Intangibles                                                 | 115           | 100           |
| Provisions                                                  | 30            | 18            |
| Accrued expenses                                            | 61            | 57            |
| Leases                                                      | 50            | 53            |
| Unrealised foreign exchange loss                            | 17            | 20            |
| Trade and other receivables                                 | -             | 6             |
| Other                                                       | -             | 10            |
|                                                             | <b>273</b>    | <b>264</b>    |
| Losses available for offset against future taxable income   | <b>4,694</b>  | <b>4,811</b>  |
| R&D offsets carried forward                                 | <b>254</b>    | <b>415</b>    |
| Total amounts recognised in profit and loss                 | <b>5,221</b>  | <b>5,490</b>  |
| <b>Amounts recognised in Equity</b>                         |               |               |
| DTA relating to share issue costs                           | 3             | 4             |
| Tax losses relating to share issue costs                    | 449           | 449           |
| Total amounts recognised in equity                          | <b>452</b>    | <b>453</b>    |
| <b>DTA</b>                                                  | <b>5,673</b>  | <b>5,943</b>  |
| Deferred tax liabilities offset against deferred tax assets | (21)          | -             |
| <b>Total offsets</b>                                        | <b>(21)</b>   | <b>-</b>      |
| <b>Closing balance</b>                                      | <b>5,652</b>  | <b>5,943</b>  |

##### (b) Deferred tax liabilities

Deferred tax liabilities balance comprises temporary differences attributable to:

|                                                             | 2025<br>000's | 2024<br>000's |
|-------------------------------------------------------------|---------------|---------------|
| Trade and other receivables                                 | 21            | -             |
| <b>Total deferred tax liabilities</b>                       | <b>21</b>     | <b>-</b>      |
| Deferred tax liabilities offset against deferred tax assets | (21)          | -             |
| <b>Closing balance</b>                                      | <b>-</b>      | <b>-</b>      |

## Notes to the Financial Statements

### For the Year Ended 30 June 2025

#### 16 Trade and Other Payables

|                              | 2025<br>000's | 2024<br>000's |
|------------------------------|---------------|---------------|
| CURRENT                      |               |               |
| Unsecured liabilities        |               |               |
| Trade payables               | 458           | 946           |
| Other payables               | 101           | 32            |
| Withholding tax on dividends | 132           | 132           |
|                              | <b>691</b>    | <b>1,110</b>  |

All amounts are short term and the carrying values are considered to be a reasonable approximation of fair value.

#### 17 Provisions

|                   | 2025<br>000's | 2024<br>000's |
|-------------------|---------------|---------------|
| CURRENT           |               |               |
| Employee benefits | 99            | 168           |
|                   | <b>99</b>     | <b>168</b>    |
|                   | <b>000's</b>  | <b>000's</b>  |
| NON-CURRENT       |               |               |
| Employee benefits | 80            | 98            |
|                   | <b>80</b>     | <b>98</b>     |

#### Provision for Employee Benefits

Provision for employee benefits represents amounts accrued for annual leave and long service leave.

The current portion for this provision includes the total amount accrued for annual leave entitlements and the amounts accrued for long service leave entitlements that have vested due to employees having completed the required period of service. Based on past experience, the Group does not expect the full amount of annual leave or long service leave balances classified as current liabilities to be settled within the next 12 months. However, these amounts must be classified as current as the Group does not have the right to defer the settlement of these amounts in the event employees wish to use their leave entitlement.

The non-current portion for this provision includes amounts accrued for long service leave entitlements that have not yet vested in relation to those employees who have not yet completed the required period of service.

The measurement and recognition criteria relating to employee benefits have been discussed at Note 2(g).

## Notes to the Financial Statements

### For the Year Ended 30 June 2025

#### 18 Issued Capital

|                                                          | 2025<br>000's | 2024<br>000's |
|----------------------------------------------------------|---------------|---------------|
| 62,646,107 (2024: 62,449,763) Ordinary shares fully paid | <b>53,254</b> | 53,103        |
| <b>Total</b>                                             | <b>53,254</b> | 53,103        |

The holders of ordinary shares are entitled to participate in dividends and the proceeds on winding up of the Company. On a show of hands at meetings of the Company, each holder of ordinary shares has one vote in person or by proxy, and upon a poll each share is entitled to one vote.

The Company does not have authorised capital or par value in respect of its shares.

#### (a) Movement in ordinary shares

|                                           | 2025<br>No.       | 2024<br>No. |
|-------------------------------------------|-------------------|-------------|
| At the beginning of the reporting period  | <b>62,449,763</b> | 62,431,719  |
| <b>Shares bought back during the year</b> |                   |             |
| <b>Shares issued during the year</b>      |                   |             |
| Employee share scheme                     | <b>196,344</b>    | 18,044      |
| At the end of the reporting period        | <b>62,646,107</b> | 62,449,763  |

#### (b) Capital Management

At this stage of the Group's growth, management's capital management objectives are to ensure that the entity continues as a going concern and to maintain a capital structure that supports future development of the Group's business. To date, capital management activities have included the issue of new shares to raise equity for investment in research and product development and other activities aimed at supporting the commercialisation and sales and marketing of its products and technologies.

Management effectively manages the Group's capital by assessing the Group's financial risks and adjusting its capital structure in response to changes in these risks and in the market. These responses include the management of debt levels, distributions to shareholders and share issues.

The Group has not entered into any other arrangements to issue further shares. However, management may consider the issue of further shares in the future in order to provide the necessary capital of future growth and/or take advantage of other opportunities.

The Group does not have any external debt and is not subject to any externally imposed capital requirements.

## Notes to the Financial Statements

### For the Year Ended 30 June 2025

#### 19 Reserves

|                                             | 2025<br>000's | 2024<br>000's |
|---------------------------------------------|---------------|---------------|
| <b>Foreign currency translation reserve</b> |               |               |
| Opening balance                             | 16            | 16            |
| <b>Share based payment reserve</b>          |               |               |
| Opening balance                             | 1,503         | 1,503         |
| <b>Total</b>                                | <b>1,519</b>  | <b>1,519</b>  |

##### (a) Foreign currency translation reserve

Exchange differences arising on translation of the foreign controlled entity are recognised in other comprehensive income - foreign currency translation reserve. The cumulative amount is reclassified to profit or loss when the net investment is disposed of.

##### (b) Share based payment reserve

The share based payment reserve is used to record the value of share-based payments provided to employees, including directors and other key management personnel, as part of their remuneration.

#### 20 Interests in Subsidiaries

##### (a) Composition of the Group

| Entity name                                    | Entity type    | Place formed/<br>Country of<br>incorporation | Ownership<br>interest %<br>2025 | Ownership<br>interest %<br>2024 | Tax residency |
|------------------------------------------------|----------------|----------------------------------------------|---------------------------------|---------------------------------|---------------|
| Antaria Pty Ltd                                | Body corporate | Australia                                    | 100                             | 100                             | Australia     |
| Sunscreen Safety Testing<br>Laboratory Pty Ltd | Body corporate | Australia                                    | 100                             | 100                             | Australia     |
| Antaria, Inc                                   | Body corporate | USA                                          | 100                             | 100                             | USA           |
| Antaria Europe, B. V.                          | Body corporate | Netherlands                                  | 100                             | 100                             | Netherlands   |

## Notes to the Financial Statements

### For the Year Ended 30 June 2025

#### 20 Interests in Subsidiaries

##### (a) Composition of the Group

\* Advance ZincTek Limited (the "head entity") and its wholly-owned Australian subsidiaries have formed an income tax consolidated group under the tax consolidation regime.

##### (b) Significant restrictions relating to subsidiaries

There are no significant restrictions over the Group's ability to access or use assets, and settle liabilities, of the Group.

#### 21 Earnings per Share

##### (a) Earnings used to calculate overall earnings per share

| 2025  | 2024  |
|-------|-------|
| 000's | 000's |
| 1,238 | (903) |

##### (b) Weighted average number of ordinary shares outstanding during the year used in calculating basic EPS

|                                                                                                      | 2025       | 2024       |
|------------------------------------------------------------------------------------------------------|------------|------------|
|                                                                                                      | No.        | No.        |
| Weighted average number of ordinary shares outstanding during the year used in calculating basic EPS | 62,495,038 | 62,452,015 |

#### 22 Contingencies

In the opinion of the Directors, the Company did not have any contingencies at 30 June 2025 (2024: None).

#### 23 Operating Segments

##### Segment information

The Group has identified its operating segments based on the internal reports that are reviewed and used by the Board of Directors (chief operating decision maker) in assessing performance and determining the allocation of resources.

The Board considers the business from a market perspective and has identified one reportable segment, the Personal Care segment which produces and distributes dispersions of mineral-only UV filters in cosmetic emollients used for sunscreen, skincare and pharmaceutical formulations, as well as alumina plate-like powders used for cosmetic applications.

## Notes to the Financial Statements

### For the Year Ended 30 June 2025

#### 23 Operating Segments

##### (a) Revenue by geographical region

In presenting information on the basis of geographical segments, segment revenue is based on the geographical location of customers.

|                                   | 2025<br>000's | 2024<br>000's |
|-----------------------------------|---------------|---------------|
| Australia                         | 2,211         | 1,675         |
| United States of America & Canada | 6,115         | 2,539         |
| Europe                            | 1,056         | 2,772         |
| Rest of the world                 | 2,257         | 2,334         |
|                                   | <b>11,639</b> | <b>9,320</b>  |

##### (b) Major customers

In the 2025 financial year, the Group's four largest customers each contributed more than 11% of total revenue and together accounted for 65% of revenue (2024: three customers accounting for 50%). All other customers individually contributed less than 4% of total revenue.

#### 24 Cash Flow Information

##### (a) Reconciliation of result for the year to cashflows from operating activities

Reconciliation of net income to net cash provided by operating activities:

|                                                                  | 2025<br>000's | 2024<br>000's |
|------------------------------------------------------------------|---------------|---------------|
| Profit for the year                                              | 1,238         | (903)         |
| Adjustments for non-cash items in profit:                        |               |               |
| - amortisation                                                   | 91            | 62            |
| - depreciation                                                   | 1,664         | 1,775         |
| - net gain / (loss) on disposal of property, plant and equipment | -             | 253           |
| - share based payments                                           | 152           | -             |
| - R&D grant                                                      | (495)         | (515)         |
| - discount on employee loans                                     | (67)          | (80)          |
| - provision for doubtful debts                                   | -             | (51)          |
| Net changes in assets and liabilities:                           |               |               |
| - (increase)/decrease in trade and other receivables             | (852)         | 1,606         |
| - (increase)/decrease in deferred tax assets                     | 786           | (87)          |
| - (increase)/decrease in prepayments                             | (183)         | 72            |
| - (increase)/decrease in inventories                             | 847           | 332           |
| - increase/(decrease) in trade and other payables                | (419)         | (156)         |
| - increase/(decrease) in provisions (Current)                    | 10            | 59            |
| - increase/(decrease) in provisions (Non-Current)                | (97)          | (128)         |
| Net cash from operating activities                               | <b>2,675</b>  | <b>2,239</b>  |

## Notes to the Financial Statements

### For the Year Ended 30 June 2025

#### 25 Key Management Personnel Disclosures

Key management personnel remuneration included within employee expenses for the year is shown below:

|                              | 2025           | 2024           |
|------------------------------|----------------|----------------|
|                              | \$             | \$             |
| Short-term employee benefits | 354,254        | 394,173        |
| Long-term benefits           | 905            | 846            |
| Post-employment benefits     | 6,530          | 6,780          |
| <b>Total</b>                 | <b>361,689</b> | <b>401,799</b> |

Refer to the remuneration report for further details.

## Notes to the Financial Statements

### For the Year Ended 30 June 2025

#### 26 Related Parties

Transactions between related parties are on normal commercial terms and conditions no more favourable than those available to other parties unless otherwise stated.

Amount receivable from related parties for the sale and purchase of goods and services are unsecured and interest free and are included in the balances of trade and other receivables. Balances are settled within normal trading terms or as per agreement with the Board. No allowance for expected credit losses has been recognised on this outstanding balance, nor have any bad debt expenses been incurred.

#### (a) The Group's main related parties are as follows:

##### (i) Key management personnel:

Any person(s) having authority and responsibilities for planning, directing and controlling the activities of the entity, directly or indirectly, including any director (whether executive or otherwise) of that entity are considered key management personnel.

For details of remuneration disclosures relating to key management personnel, refer to Note 25: Key Management Personnel Disclosure and remuneration report in the Director's Report.

Other transactions with KMP and their entities are shown below.

#### (b) Transactions with related parties

Transactions between related parties are on normal commercial terms and conditions no more favourable than those available to other parties unless otherwise stated.

The following transactions occurred with related parties:

##### (i) Sale of goods and services:

|                                                                             | 2025<br>\$ | 2024<br>\$ |
|-----------------------------------------------------------------------------|------------|------------|
| <i>Key management personnel:</i>                                            |            |            |
| <b>Lev Mizikovsky</b>                                                       |            |            |
| - Expenditure on-charged at cost to entities associated with Lev Mizikovsky | 369,729    | 27,940     |
| <i>Related parties:</i>                                                     |            |            |
| <b>Tamawood Group</b>                                                       |            |            |
| - Admin, Accounting services and expenditure on-charged at cost             | 353,914    | 210,097    |
| <b>SenterpriSys Limited</b>                                                 |            |            |
| - Expenditure on-charged at cost                                            | 66,619     | 23,097     |
| <b>Veganic SKN Limited</b>                                                  |            |            |
| - Sale of IP and PPE                                                        | -          | 29         |
| - Sale of sunscreen products                                                | 389,143    | 469,575    |
| - Admin, Accounting services and expenditure on-charged at cost             | 472,160    | 553,226    |
| - Rent                                                                      | 102,000    | -          |

## Notes to the Financial Statements

### For the Year Ended 30 June 2025

#### 26 Related Parties

##### (b) Transactions with related parties

##### (ii) Purchase of goods and services:

|                                                                                                    | 2025    | 2024    |
|----------------------------------------------------------------------------------------------------|---------|---------|
|                                                                                                    | \$      | \$      |
| <i>Key management personnel:</i>                                                                   |         |         |
| <b>Lev Mizikovsky</b>                                                                              |         |         |
| - Lease of premises                                                                                | 477,869 | 461,101 |
| <b>Geoff Acton</b>                                                                                 |         |         |
| - Provision of payroll, advisory and secretarial services by an entity associated with Geoff Acton | 219,437 | 175,347 |
| <i>Related parties:</i>                                                                            |         |         |
| <b>Tamawood Group</b>                                                                              |         |         |
| - Provision of lease premises and electricity                                                      | 136,494 | 213,494 |
| <b>SenterpriSys Limited</b>                                                                        |         |         |
| - Provision of IT equipment at cost and IT services                                                | 123,386 | 85,626  |
| <b>Winothai Pty Ltd</b>                                                                            |         |         |
| - Provision of Management services                                                                 | 20,053  | 28,497  |
| <b>Veganic SKN Limited</b>                                                                         |         |         |
| - Purchase of raw materials at cost                                                                | 453,723 | 39,909  |

##### (iii) Outstanding balances:

|                                                              | 2025    | 2024    |
|--------------------------------------------------------------|---------|---------|
|                                                              | \$      | \$      |
| <i>Key management personnel:</i>                             |         |         |
| <b>Lev Mizikovsky</b>                                        |         |         |
| - Borrowings from an entity associated with Lev Mizikovsky * |         |         |
| *These borrowings are interest free and repayable on demand. | -       | 320,000 |
| <b>Geoff Acton</b>                                           |         |         |
| - Amounts receivable**                                       | 726,241 | 726,238 |
| - Amounts payable                                            | 1,094   | -       |

\*\*These borrowings are unsecured and earn interest at 3.5%.

## Notes to the Financial Statements

### For the Year Ended 30 June 2025

#### 26 Related Parties

##### (b) Transactions with related parties

|                             | 2025   | 2024    |
|-----------------------------|--------|---------|
|                             | \$     | \$      |
| <i>Related parties:</i>     |        |         |
| <b>Tamawood Group</b>       |        |         |
| - Amounts receivable        | -      | 40,361  |
| - Amounts payable           | 86,190 | 225,132 |
| <b>SenterpriSys Limited</b> |        |         |
| - Amounts receivable        | 35,624 | 35,500  |
| - Amounts payable           | 3,678  | 74,362  |
| <b>Veganic SKN Limited</b>  |        |         |
| - Amounts receivable        | 63,825 | 227,047 |
| - Amounts payable           | 10,454 | 70,652  |

#### 27 Financial Risk Management

This note discloses the Group's objectives, policies and processes for managing and measuring these risks.

The Group is primarily exposed to the following financial risks:

- Market risk - currency risk and cash flow interest rate risk
- Credit risk
- Liquidity risk

##### Objectives, policies and processes

The Board has overall responsibility for the determination of the Group's risk management objectives and policies and whilst remaining ultimately responsible for them, it has delegated the authority to management for developing and operating processes that ensure the effective implementation of the objectives and policies of the Group's finance function. The Group's risk management policies and objectives are therefore designed to minimise the potential impact of these risks on the results of the Group where such impact may be material.

The Group's financial instruments consist mainly of deposits with banks, short-term investments, accounts receivable and accounts payable.

The overall objective of the Board is to set policies that seek to reduce risk as far as possible without unduly affecting the Group's competitiveness and flexibility. Specific information regarding the mitigation of each financial risk to which the Group is exposed is provided below.

## Notes to the Financial Statements

### For the Year Ended 30 June 2025

#### 27 Financial Risk Management

##### (a) Market risk

##### *(i) Foreign currency risk*

Exposures to currency exchange rates arise from the Company's overseas sales and purchases, which are primarily denominated in US dollars and Euro.

The Company's policy is that all foreign currency transactions are settled on a spot rate basis. There are no hedge facilities or other forward contract facilities in place.

In order to monitor the continuing effectiveness of the policy, the Board receives reports on its product pricing strategy together with data relating to any major fluctuations in foreign currencies. The Company's policy to mitigate foreign currency risk is to adjust selling prices for its products to reflect movements in foreign currencies.

Foreign currency denominated financial assets and liabilities, translated into Australian Dollars at the closing rate, are as follows:

|                                    | 2025         | 2024       |
|------------------------------------|--------------|------------|
|                                    | 000's        | 000's      |
| <b>Financial assets</b>            |              |            |
| Cash deposits in USD               | 372          | 25         |
| Cash deposits in Euro              | 77           | 76         |
| Customers denominated in USD       | 1,782        | 720        |
| Customers denominated in Euro      | 14           | 28         |
| <b>Financial liabilities</b>       |              |            |
| Trade payables denominated in USD  | (257)        | (89)       |
| Trade payables denominated in Euro | (8)          | (196)      |
| <b>Net exposure</b>                | <b>1,980</b> | <b>564</b> |

##### *(ii) Interest rate risk*

The Group has no borrowings and has no current exposure to interest rate risk on borrowings.

The Group's minimum exposure to market interest rate relates to its cash investments which are minimal.

The Company adopts a policy of minimising exposure to interest rate risk. A +/-1% change in interest rates would change the net interest revenue by +/- \$6,290 per annum (2024: +/- \$1,630) on cash held at year end.

##### *(iii) Foreign currency sensitivity analysis*

The following table illustrates the sensitivity of the net result for the year and equity in regards to the Company's financial assets and financial liabilities and the US Dollar – Australian Dollar exchange rate and the Euro – Australian Dollar exchange rate. There have been no changes in the assumptions calculating this sensitivity from prior years. The sensitivity analysis is based on the foreign currency financial instruments held at the reporting date.

The sensitivity analysis assumes a +/- 5% change of the Australian Dollar / US Dollar exchange rate for the year ended 30 June 2025 (30 June 2024: 5%). A +/- 5% change is also assumed for the Australian Dollar / Euro exchange rate (30 June 2024: 5%). Both of these percentages have been determined based on the historical market volatility in exchange rates.

## Notes to the Financial Statements

### For the Year Ended 30 June 2025

#### 27 Financial Risk Management

|             | 2025<br>000's |     | 2024<br>000's |     |
|-------------|---------------|-----|---------------|-----|
|             | +5%           | -5% | +5%           | -5% |
| <b>USD</b>  |               |     |               |     |
| Net results | (95)          | 95  | (33)          | 33  |
| Equity      | (95)          | 95  | (33)          | 33  |
| <b>Euro</b> |               |     |               |     |
| Net results | (4)           | 4   | 5             | (5) |
| Equity      | (4)           | 4   | 5             | (5) |

Exposures to foreign exchange rates vary during the year depending on the volume of overseas transactions. Nonetheless, the analysis above is considered to be representative of the Group's exposure to foreign currency risk.

#### (b) Credit risk

Credit risk refers to the risk that a counterparty will default on its contractual obligations resulting in a financial loss to the Group.

Credit risk arises from cash and cash equivalents and deposits with banks and financial institutions, as well as credit exposure to wholesale and retail customers, including outstanding receivables and committed transactions.

The Group conducts transactions with the following major type of counterparties:

Receivables counterparties: The majority of sales to the Group customers are made on open terms. As part of managing this risk, new customers can be required to make (part) payment for goods prior to shipping initial orders

To manage credit risk, the Group maintains group wide procedures covering the application for credit approvals, granting and renewal of counterparty limits and regular monitoring of exposure against these limits. The Group monitors its trade receivables balances on an ongoing basis and also maintains a credit insurance policy where appropriate.

The credit risk for liquid funds and other short-term financial assets is considered negligible, since the counterparties are reputable banks with high quality external credit ratings.

#### (c) Liquidity risk

Liquidity risk arises from the Group's management of working capital and the finance charges and principal repayments on its debt instruments. It is the risk that the Group will encounter difficulty in meeting its financial obligations as they fall due.

The Group manages its liquidity needs by carefully monitoring scheduled debt servicing payments for long-term financial liabilities as well as cash-outflows due in day-to-day business.

At the reporting date, these reports indicate that the Group expected to have sufficient liquid resources to meet its obligations under all reasonably expected circumstances.

## Notes to the Financial Statements

### For the Year Ended 30 June 2025

#### 27 Financial Risk Management

##### Liquidity risk

|                        | 2025<br>000's | 2024<br>000's |
|------------------------|---------------|---------------|
| Current assets         | 16,422        | 15,701        |
| Current liabilities    | (1,208)       | (2,013)       |
| <b>Working capital</b> | <b>15,214</b> | <b>13,688</b> |

The table below reflects an undiscounted contractual maturity analysis for financial liabilities.

The timing of cash flows presented in the table to settle financial liabilities reflects the earliest contractual settlement dates. The timing of expected outflows is not expected to be materially different from contracted cashflows. The amounts disclosed in the table are the undiscounted contracted cash flows and therefore the balances in the table may not equal the balances in the consolidated statement of financial position due to the effect of discounting.

|                                              | Within 1 Year |               | 1 to 5 Years  |               | Over 5 Years  |               | Total         |               |
|----------------------------------------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|
|                                              | 2025<br>000's | 2024<br>000's | 2025<br>000's | 2024<br>000's | 2025<br>000's | 2024<br>000's | 2025<br>000's | 2024<br>000's |
| <b>Financial liabilities due for payment</b> |               |               |               |               |               |               |               |               |
| Trade and other payables                     | 691           | 1,110         | -             | -             | -             | -             | 691           | 1,110         |
| Lease liabilities                            | 474           | 479           | 1,020         | 1,333         | -             | -             | 1,494         | 1,812         |
| Borrowings                                   | -             | 320           | -             | -             | -             | -             | -             | 320           |
| <b>Total contractual outflows</b>            | <b>1,165</b>  | <b>1,909</b>  | <b>1,020</b>  | <b>1,333</b>  | <b>-</b>      | <b>-</b>      | <b>2,185</b>  | <b>3,242</b>  |

The timing of expected outflows is not expected to be materially different from contracted cashflows.

#### 28 Events Occurring After the Reporting Date

No other matters or circumstances have arisen since the end of the financial year which significantly affected or could significantly affect the operations of the Group, the results of those operations, or the state of affairs of the Group in future financial years.

## **Notes to the Financial Statements**

### **For the Year Ended 30 June 2025**

#### **29 Company Details**

**The registered office of the company is:**

Advance ZincTek Limited  
1821, Ipswich Road  
Rocklea, QLD 4106

**Manufacturing Facilities**

Unit 1 & 2, 81 Shettleston Street  
Rocklea, QLD 4106

**Overseas Warehouse Facilities**

**United States**

464 Bronze Way  
Dallas, Texas 75236

**Europe**

**Mainfreight**

Brede Steeg 1  
s'Heerenberg 7041 GV  
Netherlands

## Consolidated entity disclosure statement

| Entity name                                    | Entity type    | Place formed /<br>Country of<br>incorporation | Ownership<br>interest %<br>2025 | Tax residency |
|------------------------------------------------|----------------|-----------------------------------------------|---------------------------------|---------------|
| Advance ZincTek Limited                        | Body Corporate | Australia                                     | N/A                             | Australia*    |
| Antaria Pty Ltd                                | Body corporate | Australia                                     | 100                             | Australia*    |
| Sunscreen Safety Testing<br>Laboratory Pty Ltd | Body corporate | Australia                                     | 100                             | Australia*    |
| Antaria, Inc                                   | Body corporate | USA                                           | 100                             | USA           |
| Antaria Europe, B. V.                          | Body corporate | Netherlands                                   | 100                             | Netherlands   |

Advance ZincTek Limited (the "head entity") and its wholly-owned Australian subsidiaries have formed an income tax consolidated group the under the tax consolidation regime.

## Independent auditor's report to the members of Advance ZincTek Limited

### Report on the audit of the financial report



#### Our opinion on the financial report

In our opinion, the accompanying financial report of Advance ZincTek Limited (the Company) and its subsidiaries (the Group), is in accordance with the *Corporations Act 2001*, including:

- giving a true and fair view of the Group's financial position as at 30 June 2025 and of its financial performance for the year then ended; and
- complying with Australian Accounting Standards and the *Corporations Regulations 2001*.

#### What was audited?

We have audited the financial report of the Group, which comprises:

- the statement of financial position as at 30 June 2025,
- the statement of profit or loss and other comprehensive income for the year then ended,
- the statement of changes in equity for the year then ended,
- the statement of cash flows for the year then ended,
- notes to the financial statements, including material accounting policy information,
- the consolidated entity disclosure statement, and
- the directors' declaration.

#### Basis for opinion

We conducted our audit in accordance with Australian Auditing Standards. Our responsibilities under those standards are further described in the *Auditor's responsibilities for the audit of the financial report* section of our report. We are independent of the Group in accordance with the auditor independence requirements of the *Corporations Act 2001* and the ethical requirements of the Accounting Professional & Ethical Standards Board's APES 110 *Code of Ethics for Professional Accountants (including Independence Standards)* (the Code) that are relevant to our audit of the financial report in Australia. We have also fulfilled our other ethical responsibilities in accordance with the Code.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

## Key audit matters

Key audit matters are those matters that, in our professional judgement, were of most significance in our audit of the financial report of the current period. These matters were addressed in the context of our audit of the financial report as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.

| Revenue Recognition               | Area of focus<br>(refer also to notes 2 & 5)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | How our audit addressed the key audit matter                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|-----------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                   | <p>The group generated \$11.6 million of sales revenue in the year ended 30 June 2025. This relates to sale of goods to customers which are recognised in the financial statements when revenue can be measured reliably, it is probable that economic benefits associated with the transaction will flow to the consolidated entity and at the point in time when the customer takes undisputed delivery of the goods.</p> <p>There is a risk of incorrect timing of revenue recognition due to fraud or misstatements.</p> <p>Due to this, we consider revenue recognition to be a key audit matter.</p> | <p>Our audit procedures included:</p> <ul style="list-style-type: none"> <li>— An analysis of sales transactions to verify the correct treatment in accordance with the AASB 15 revenue recognition criteria;</li> <li>— On a sample basis, comparing sales transactions to delivery documents;</li> <li>— Checking for significant credit notes issued subsequent to year end;</li> <li>— Reconciling cash payments received subsequent to year end against accounts receivable balances as at 30 June 2025; and</li> <li>— Assessing the adequacy of the allowance for expected credit losses.</li> <li>— We have also assessed the adequacy of disclosures in the notes to the financial statements.</li> </ul> |
| Inventory valuation and existence | Area of focus<br>(refer also to notes 2 & 10)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | How our audit addressed the key audit matter                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|                                   | <p>The group held inventory of \$11.9 million as at 30 June 2025 across multiple locations.</p> <p>Inventory is costed using absorption costs and is carried at the lower of cost and net realisable value. This balance accounts for approximately 31% of the group's assets as at 30 June 2025 and misstatements in this balance may have a considerable impact on the group's profit from continuing</p>                                                                                                                                                                                                | <p>Our audit procedures included:</p> <ul style="list-style-type: none"> <li>— Attending various stock counts during and at year end at locations holding material inventory values ensuring appropriate cut-off of goods in or out of inventory;</li> <li>— Obtaining confirmations from third party's holding stock on behalf of the group as at 30 June 2025;</li> </ul>                                                                                                                                                                                                                                                                                                                                        |

operations. As a consequence, we consider inventory existence and valuation to be a key audit matter.

- Agreeing on sample basis the cost components of inventory to actual prices;
- Assessing the reasonableness of costing for WIP and finished goods; and
- Assessing whether an appropriate provision has been made for slow moving or obsolete inventory items.
- We have also assessed the adequacy of disclosures in the notes to the financial statements.

## Other information

The directors are responsible for the other information. The other information comprises the information included in the Group's annual report for the year ended 30 June 2025, but does not include the financial report and our auditor's report thereon.

Our opinion on the financial report does not cover the other information and accordingly we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial report, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial report or our knowledge obtained in the audit or otherwise appears to be materially misstated.

If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

## Responsibilities of the directors for the financial report

The directors of the Company are responsible for the preparation of:

- the financial report (other than the consolidated entity disclosure statement) that gives a true and fair view in accordance with Australian Accounting Standards and the *Corporations Act 2001*; and
- the consolidated entity disclosure statement that is true and correct in accordance with the *Corporations Act 2001*, and

for such internal control as the directors determine is necessary to enable the preparation of:

- the financial report (other than the consolidated entity disclosure statement) that gives a true and fair view and is free from material misstatement, whether due to fraud or error; and
- the consolidated entity disclosure statement that is true and correct and is free of misstatement, whether due to fraud or error.

In preparing the financial report, the directors are responsible for assessing the ability of the Group to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the Group or to cease operations, or have no realistic alternative but to do so.

## Auditor's responsibilities for the audit of the financial report

Our objectives are to obtain reasonable assurance about whether the financial report as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with the Australian Auditing Standards will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this financial report.

A further description of our responsibilities for the audit of the financial report is located at the Auditing and Assurance Standards Board website at:

[https://www.auasb.gov.au/media/bwvjcgre/ar1\\_2024.pdf](https://www.auasb.gov.au/media/bwvjcgre/ar1_2024.pdf)

This description forms part of our auditor's report.

## Report on the Remuneration Report



### Our opinion on the Remuneration Report

In our opinion, the Remuneration Report of Advance ZincTek, for the year ended 30 June 2025, complies with section 300A of the *Corporations Act 2001*.

### What was audited?

We have audited the Remuneration Report included in the directors' report for the year ended 30 June 2025.

## Responsibilities

The directors of the Company are responsible for the preparation and presentation of the Remuneration Report in accordance with section 300A of the *Corporations Act 2001*. Our responsibility is to express an opinion on the Remuneration Report, based on our audit conducted in accordance with Australian Auditing Standards.

William Buck

**William Buck (Qld)**  
ABN 21 559 713 106

M. Monaghan

**M J Monaghan**  
Partner  
Brisbane, 29 August 2025

## Corporate Governance Statement

30 June 2025

The objective of the Board of Advance ZincTek Ltd ("ANO") is to create and deliver long term shareholder value through a range of diversified product sales and development in cosmetics and sunscreen.

ANO and its subsidiaries operate as a single economic activity under a unified Board and management. As such, the Board's corporate governance arrangements apply to all entities within the economic Group ("the Group").

ANO has adopted the recommendations of the ASX Corporate Principles Edition 4. ANO has completed and lodged an Appendix 4G in conjunction with the lodgement of its Annual Report. ANO has clearly explained in its governance strategy where principles have been adopted and if not why not.

The company's charters, committees and corporate governance principles are on our website [www.advancezinctek.com](http://www.advancezinctek.com).

## Shareholder Information

30 June 2025

### ASX Additional Information

Additional information required by the ASX Listing Rules and not disclosed elsewhere in this report is set out below. This information is effective as at 25 August 2025.

### Voting rights

#### Ordinary Shares

On a show of hands, every member present at a meeting in person or by proxy shall have one vote and upon a poll each share shall have one vote.

#### Options

No voting rights.

| Holding          | Ordinary shares   |                |
|------------------|-------------------|----------------|
|                  | No. of shares     | No. of holders |
| 1 - 1,000        | 240,676           | 533            |
| 1,001 - 5,000    | 624,100           | 260            |
| 5,001 - 10,000   | 491,660           | 67             |
| 10,001 - 100,000 | 3,271,562         | 101            |
| 100,001 and over | 58,018,109        | 46             |
|                  | <b>62,646,107</b> | <b>1,007</b>   |

There were 261 holders of less than a marketable parcel of ordinary shares.

## Shareholder Information

### 30 June 2025

#### Substantial shareholders

The number of substantial shareholders and their associates are set out below:

#### Twenty largest shareholders

| Holding                                                                                        | Ordinary shares   |               |
|------------------------------------------------------------------------------------------------|-------------------|---------------|
|                                                                                                | No. of shares     | % of shares   |
| POLTICK PTY LTD                                                                                | 24,517,975        | 39.14%        |
| ANKLA PTY LTD                                                                                  | 11,331,978        | 18.09%        |
| KEARNEY ETHICAL INVESTMENTS PTY LTD                                                            | 5,267,461         | 8.41%         |
| RAINROSE PTY LTD                                                                               | 4,185,615         | 6.68%         |
| MR BRIAN MAURICE KEARNEY & MRS MIRELLA UGHETTA DORICA KEARNEY<br><KEARNEY ETHICAL INV S/F A/C> | 1,899,882         | 3.03%         |
| CITICORP NOMINEES PTY LIMITED                                                                  | 1,303,235         | 2.08%         |
| BNP PARIBAS NOMINEES PTY LTD <IB AU NOMS RETAILCLIENT>                                         | 717,235           | 1.14%         |
| MR EDWIN GIOVANNI DIAZ                                                                         | 540,140           | 0.86%         |
| MR KEITH WILLIAM KERRIDGE <AUSTRALASIAN ASSET MGMT A/C>                                        | 500,000           | 0.80%         |
| THE L AND R SUPER FUND PTY LTD <THE L & R SUPER FUND A/C>                                      | 472,562           | 0.75%         |
| MELBOURNE CORPORATION OF AUSTRALIA PTY LTD                                                     | 400,000           | 0.64%         |
| MRS NICOLE LOUISE BOWERS                                                                       | 370,444           | 0.59%         |
| ROLLEE PTY LTD                                                                                 | 367,821           | 0.59%         |
| MR GEOFFREY BROCKWELL ACTON                                                                    | 352,429           | 0.56%         |
| GADIA INVESTMENTS PTY LTD <DIAZ SUPERFUND A/C>                                                 | 307,339           | 0.49%         |
| MR GEOFFREY BROCKWELL ACTON                                                                    | 290,000           | 0.46%         |
| MR RADE DUDUROVIC & MRS JACQUELINE JEANETTE DUDUROVIC <R&J<br>SUPERANNUATION FUND A/C>         | 268,772           | 0.43%         |
| MR KEVIN RICHARD GOULD                                                                         | 268,309           | 0.43%         |
| MR KEITH WILLIAM KERRIDGE                                                                      | 265,000           | 0.42%         |
| VELROSSO PTY LTD <HARVEY 1995 DISC A/C>                                                        | 250,000           | 0.40%         |
|                                                                                                | <b>53,876,197</b> | <b>86.00%</b> |

## **Disclosures Regarding Forward Looking Statements**

This Annual Report includes forward looking statements that have been based on Advance ZincTek Limited's ("ANO") current expectations and predictions about future events including ANO's intentions.

These forward looking statements are, however, subject to inherent risks, uncertainties and assumptions that could cause actual results, performance or achievements of ANO to differ materially from the expectations and predictions, express or implied, in such forward looking statements.

None of ANO, its officers, directors, the persons named in this Annual Report with their consent, or the persons involved in the preparation of this, Annual Report makes any representation or warranty (express or implied) as to the accuracy or likelihood of any forward looking statements. You are cautioned not to place reliance on these statements in the event that the outcome is not achieved. These statements reflect views and options as at the date of this Annual Report.

We obviously can't predict the situation in Europe with the war, the issues between China and the USA and the impact of USA tariffs will have on our views.